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Abstract 
A pressing need exists for antigen-specific immunotherapies (ASIT) that induce selective 
tolerance in autoimmune disease while avoiding deleterious global immunosuppression. 
Multivalent soluble antigen arrays (SAgAPLP:LABL), consisting of a hyaluronic acid (HA) linear 
polymer backbone co-grafted with multiple copies of autoantigen (PLP) and cell adhesion 
inhibitor (LABL) peptides, are designed to induce tolerance to a specific multiple sclerosis (MS) 
autoantigen. Previous in vivo studies established that SAgAPLP:LABL was therapeutic in 
experimental autoimmune encephalomyelitis (EAE), a murine model of MS. This dissertation 
sought to elucidate SAgA therapeutic cellular mechanisms while identifying therapeutic 
molecular properties. In Chapter 2, the role of two-signal co-delivery was explored by evaluating 
EAE in vivo results in conjunction with in silico molecular dynamics simulations and 
nanomaterial properties for various covalent and physical combinations of HA, PLP, and LABL. 
We found that co-delivery of both primary autoantigen and secondary inhibitory signal was 
necessary for therapeutic efficacy against EAE. In Chapters 3 and 4, the SAgAPLP:LABL cellular 
mechanism was investigated in a model B cell system by evaluating binding, specificity, and 
signaling modulation in vitro. Here, we developed click-conjugated cSAgAPLP:LABL which, unlike 
SAgAPLP:LABL, employed a non-hydrolyzable linker chemistry to conjugate PLP and LABL to 
HA. cSAgAPLP:LABL exhibited significantly enhanced in vivo efficacy compared to hydrolyzable 
SAgAPLP:LABL. We found that cSAgAPLP:LABL acted through high avidity, antigen-specific B cell 
binding, targeting the B cell receptor (BCR) to dampen BCR-mediated signaling. Our 
conclusions point to induction of antigen-specific B cell anergy as the cSAgAPLP:LABL therapeutic 
mechanism and present a promising option for ASIT.  
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1. Multivalent Nanomaterials: Learning from Vaccines and Progressing to Antigen-
Specific Immunotherapies 
The use of nanomaterials such as polymers and colloids in medicine has grown 
dramatically over the past two decades 1. While the applications vary greatly, many have 
explored the ability of these materials to generate an immune response. Nanomaterials can be 
engineered to have specific characteristics such as size, charge, and shape, properties that 
influence biodistribution and immune response. Furthermore, current techniques allow 
researchers to modify nanomaterial display, such as the number, density, and ratio of ligands or 
antigens on the nanomaterial itself. Although appreciated retrospectively, prophylactic vaccines 
used to invoke a protective immune response have primarily been colloidal microparticles, which 
have paved the road towards the development of therapeutic nanomaterials 2. To help explain 
immune response to nanomaterials, research has continued to explore linkages between 
nanomaterial characteristics, route of administration, transport, final deposition site, and the 
resultant immune response 2,3. In particular, researchers must continue to probe the ability of 
nanomaterials presenting small molecules, peptides, or other ligands to elicit specific and 
sustained immune responses not only in the context of vaccines, but also for other 
immunomodulatory therapies. Finally, new insights for designing multivalent nanomaterial 
immunotherapies for autoimmune diseases should emerge when considering the backdrop of 
vaccine design.   
1.1 Mechanisms of the Immune Response 
Unlike many other organ systems of the body, the immune system has a unique and vital 
conscious component in its ability to distinguish ‘self’ (endogenous) and ‘non-self’ (exogenous) 
antigens. Critical studies reviewed elsewhere have laid the groundwork for identifying 
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mechanisms and communication networks between specialized cell types and resultant 
immunological responses. In general, a healthy immune system has the ability to act in an 
antigen-specific manner and can opt to make several decisions after recognition of antigen: 
recognize antigen as 1) “self” and elicit a non-response to that antigen, 2) “non-self” and elicit a 
non-response (generally termed anergy), or 3) “non-self” evoking an immune response against 
that antigen, potentially leading to immunological memory to that antigen. Specific 
discrimination between “self” and “non-self” antigens is an essential feature of the immune 
system. Breakdown in this recognition is thought to be a key player in autoimmune diseases.  
One simple model that has helped researchers describe this discrimination phenomenon is 
the 2-signal model of lymphocyte activation, suggesting the context of antigen presentation helps 
determine the downstream immune response. In general, interaction of naive B or T cells with 
antigen is not sufficient to initiate an immune response. It has been proposed that lack of 
stimulation is a mechanism whereby autoreactive B and T cells, which have evaded negative 
selection processes, are prevented from reacting with self-antigens in the periphery, thereby 
preventing them from causing autoimmune disease. The model proposes that antigen delivered 
with a secondary activation “context” signal (i.e. costimulation) can evoke a robust immune 
response toward the offending antigen and can lead to long-term immunological memory. Many 
of these costimulatory molecules are thought to be mediated by cell-cell interactions of surface 
receptors (e.g. CD28:CD80, CD40:CD40L) 4-6. Soluble mediators such as innate immune 
receptor ligands (e.g. lipopolysaccharide, Poly I:C) have also been shown to enhance antigen-
specific immune response and continue to be actively researched as adjuvants in vaccine 
formulations 7,8. Conversely, recent evidence shows secondary signals can also regulate the 
immune response, suggesting immunological memory can be reprogrammed to elicit an anergic 
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response leading to antigen-specific immune tolerance 9-11. While new mechanisms of immune 
system activation are being discovered at a rapid pace, many identified mechanisms of immune 
response can be applied to this 2-signal approach to antigen recognition, especially for vaccine 
formulation strategies classically defined as antigen (signal 1) and adjuvant (signal 2).    
1.2 Introduction to Vaccines 
Vaccines have historically used colloidal suspensions in the 10 µm range to stimulate 
adaptive immunity and to provide prophylactic protection from infectious diseases 12,13. The 
immune system can be primed to prevent and eliminate disease by exposure to a weakened form 
of the causative pathogen 14-16. As vaccines have evolved, they have moved toward incorporating 
safer, more purified pathogen components. Subunit or recombinant vaccines, which deliver only 
necessary protective antigens, help to eliminate exposure to portions of the pathogen that may 
cause unnecessary reactivity or harmful side effects. Unfortunately, simple delivery of specific 
antigen epitopes without immunogenic components (i.e. innate immune system agonists) is often 
not sufficient to produce long-lasting protective immunity. Therefore, subunit vaccines have 
been designed to deliver antigen with immunogenic particles, or adjuvants 17.  
While there is no unified mechanism of action for the array of vaccines currently on the 
market, the success of colloidal or emulsion-based adjuvants is hypothesized to lie in their ability 
to 1) enhance and/or stabilize the physical presentation of antigen by acting as an antigen carrier 
and/or depot, and 2) provide direct stimulatory signals critical for immune cell recruitment and 
activation. Characteristics of the interaction between adjuvant and antigen such as surface 
adsorption, changes in protein folding, and antigen epitope stability impact the release of stable 
antigen as well as the potency and long-term efficacy of a vaccine 18.  
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Of the adjuvants approved for human use, the majority have been postulated to form a 
depot at the injection site 19. Depots are thought to provide high local concentration of antigen 
and extend its release over time, allowing for adequate recruitment of immune cells required for 
establishing long-term immunological memory. Adjuvants also enhance antigen recognition and 
uptake by making antigen more particulate in nature. Antigens adsorbed to the surface of 
polydisperse nanometer- to micron-sized aluminum adjuvant particles in suspension, or delivered 
with oil droplets within an emulsion, fall within a size range comparable to that of a virus or 
bacteria, and thus more readily undergo phagocytosis by APCs 14,20. Consequently, portions of, if 
not entire, viruses and bacteria have been used to create nanoparticles to potentiate immune 
responses. Intrinsically immunogenic particles such as virus-like particles (VLPs), virosomes, 
and AS04 provide costimulatory signals for specific innate immune-stimulating receptors 18,20. 
For instance, the highly repetitive viral proteins delivered on VLPs can effectively stimulate the 
pattern recognition receptors (PRRs) of the innate immune system. The adjuvant AS04 combines 
aluminum phosphate and monophosphoryl lipid A (MPL), a less reactive and less toxic 
derivative of LPS, to activate TLR4 on the cell surface and thereby initiate the TLR4 signaling 
pathway 21,22. The use of molecular adjuvants provides the opportunity to more specifically direct 
immune responses and, in the case of MPL, can help augment the antibody response as much as 
100-fold 23. 
 Though adjuvants have played a vital role in creating effective vaccines out of safer and 
more purified antigens, there remains room for improvement. As mentioned above, antigens 
associated with adjuvants may suffer from unknown or inadequate structure, stability, 
orientation, or organization. Aluminum adjuvants were commonly thought to form depots; 
however, there is evidence to suggest otherwise depending on how the antigen associates with 
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the aluminum particle. Antigens within aluminum-adjuvanted vaccines may bind the particle by 
ligand exchange, especially when the antigen contains phosphate groups, or may be adsorbed to 
the surface of the aluminum via electrostatic or hydrophobic interactions. Upon contact with 
interstitial fluid, aluminum begins to degrade and antigen adsorbed to the particle is particularly 
prone to elute from the aluminum, such that both may diffuse from the injection site. Regardless, 
aluminum helps maintain the antigen at a high concentration at the injection site while building 
robust immunity to the antigen, possibly by inducing necrosis and inflammation to attract APCs 
7,13,24,25. Similarly, antigen mixed with MF59 does not incorporate into the oil droplets to any 
appreciable extent, but is supposedly better recognized within the microenvironment created by 
the emulsion antigen 13,26. As our understanding of immune system complexity has improved, the 
importance of antigen presentation (and even secondary signal presentation) in the appropriate 
time and space has become apparent. Nanomaterials such as colloids and polymers offer a highly 
capable delivery system to covalently anchor and more efficiently deliver antigens or ligands 
directing the immune response in an orientation and pattern that serves to induce desired 
responses. 
 
2. Multivalent Nanomaterials 
Multivalent nanomaterials are rooted in historic vaccine approaches and present new 
opportunities for restoring immune tolerance. Nanomaterials can be synthesized from diverse 
raw materials with unique physical and chemical properties well suited for immune modulation 
and multivalent antigen presentation. Several materials and architectures have been explored as 
nanomaterial scaffolds for ligand presentation, such as virions, VLPs, linear polymers, polymeric 
nanoparticles, liposomes, dendrimers, globular proteins, carbon nanotubes, gold nanoparticles 
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(GNPs), and others (Figure 1). VLPs, for instance, have traditionally been used in nanoparticle 
vaccines, but have recently found use as scaffolds in the development of new nanomaterials due 
to their structural stability and manipulability 27-29.  
As previously mentioned, some nanomaterials are used in vaccines to bolster immunity 
using intrinsically immunogenic constituents (i.e. VLPs, TLRs); other materials, such as 
polymers and liposomes, can remain more immunologically silent. Selecting immunologically 
inert scaffolds and linker materials reduces the risk of unintended reactivity toward degradation 
products and may favor specific immune response against the antigen. Conversely, selecting 
intrinsically immunogenic backbone materials provides a molecular adjuvant to enhance 
immunogenicity toward the given antigen. While a multitude of nanomaterials can be created to 
effect an immune response, this review will briefly overview properties of nanomaterials that 
affect immune response and then explore multivalent linear polymeric nanomaterials, especially 
in the context of antigen-specific immune tolerization.  
2.1 Valency 
Multivalency is indicative of multiple copies of the same ligand on a polymer or colloid. 
Multivalent nanomaterials specified in this review are distinct from multivalent vaccines that 
deliver several different antigens or epitopes (i.e. to provide cross-protection). Also, we refer to 
ligands derived specifically from immunogenic epitopes as antigenic ligands. In other cases, we 
refer more generally to ligands as primary (antigenic) or secondary signals. Although the jargon 
deviates slightly from vaccinology, the terms provide useful reference points as we proceed to 
antigen-specific immunotherapies. Many multivalent nanomaterials also contain a linker 
attaching the ligand to the selected material. Multivalent ligands interact with cell surface 
receptors to effect a biological response through various mechanisms: 1) decreasing ligand 
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binding off-rate by the chelate effect, 2) subsite binding in a secondary region of the receptor, 3) 
steric stabilization and blocking of competing binding agents, 4) statistical rebinding of ligands 
due to their proximity and high local concentration, and 5) receptor clustering to activate 
signaling pathways 30. Whitesides et al have discussed the importance of multivalency as a 
design strategy to target viruses, toxins, proteins, antibodies, and cell surfaces, as many of these 
biological targets have multiple repetitive binding sites 31. 
Ultimately, choice of scaffold affects the size, shape, valency, ligand spacing, 
conformation, rigidity, and hydrophilicity of the multivalent array, all of which can have 
significant biological effects 32 (Figure 2). For example, the physical characteristics of the chosen 
backbone material and linker affect a molecule’s interactions with biological surfaces, as well as 
size of the molecule and its geometric relationship to other surface ligands 33-37. Linker size and 
hydrophobicity play a role in appropriate ligand spacing, illustrated in multiple studies such as 
with GNPs 38,39. Ligand valency (Figure 2a) and spacing (Figure 2b) are important determinants 
for the strength and nature of a nanomaterial-immune cell interaction, and therefore affect 
biological recognition and immune response. Increasing valency can increase the apparent 
binding for a given multivalent ligand through avidity 31, and also influence cell surface receptor 
clustering to initiate or amplify signal transduction 30,34,40-43.  
Increased ligand binding creates another consideration for multivalent nanomaterials, 
which is the potential for increased clearance in vivo by macrophages, in particular for liposomes 
with high ligand densities 44-48. APC uptake can be further amplified through addition of 
secondary targeting ligands 49. This is an important consideration depending on the application. 
For many therapeutics, phagocytosis by macrophages is undesired, but for some vaccines 
improved particle uptake may augment an immunogenic response 16. Interplay of ligand valency, 
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density, linker length and flexibility, and incorporation of secondary ligands is important for 
biological effector function, as these properties drive receptor engagement, interaction, signaling, 
and phagocytic uptake.  
2.2 Size 
In addition to the backbone, linker, and ligand properties, size influences transport and 
recognition of the nanomaterial. Size of the nanomaterial is known to alter the drug distribution 
and pharmacokinetic profiles, in part by affecting diffusion and cellular uptake 50. Nanomaterials 
most likely will have one of four fates after peripheral administration: 1) smaller materials (<10 
nm) tend to drain to capillaries and into systemic circulation, 2) negatively charged 
nanomaterials between ~10-70 nm favor lymphatic drainage, 3) larger nanomaterials (>70 nm) 
have a higher probability of remaining at the injection site, and 4) these larger nanomaterials, 
especially when cationic, may be phagocytosed and potentially actively transported to lymph 
nodes 51-54.  
Studies show particle size is an important determinant for vaccine immunogenicity 39,55. 
Often, large foreign particles are inherently immunogenic 56,57. Traditional adjuvant vaccines 
such as aluminum salts typically create an antigen:adjuvant depot at the injection site. As alluded 
to above, recruitment of immune cells to the injection site, particularly pAPCs, is considered a 
primary mechanism for activating a protective immune response. As such, large (>70 nm) 
nanomaterials may be ideal antigen carriers for traditional prophylactic protective vaccines. In 
contrast, vaccines that do not necessarily require immune cell recruitment and active transport 
could be delivered directly to the lymphatic tissue by selecting 10-70 nm nanomaterials. Very 
small (<10 nm) nanomaterials may be plagued by high clearance rates 58. 
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2.3 Shape 
Several researchers have found that shape of a nanomaterial might also play a role in 
transport. Like size, shape affects particle behaviors such as diffusion and deposition or adhesion 
to vessel walls 50,59. Furthermore, shape can determine surface area and the shear forces 
experienced by particles in systemic circulation, affecting particle biodistribution. For example, 
linear, polymeric nanomaterials and elongated, elliptical particles are observed to have longer 
half-lives 60,61 and an increased propensity to deposit in the liver compared to spherical particles 
and disk-shaped particles, which tend to deposit in the lungs and heart of mice 62,63. The 
difference in distribution and systemic persistence between the shapes could perhaps be due to 
alignment with flow and reduced adhesion to vessel walls 61,64,65.  
Other researchers have found that nanoparticle size and shape can influence not only 
biodistribution, but also cellular response 63,65,66. Linear and more elongated nanomaterials are 
not easily phagocytized by macrophages or endocytosed by endothelial cells 67,68. The decreased 
clearance rate could contribute to the longer half-life of linear or elongated nanomaterials 
compared to more spherical nanomaterials 50,63,69-71.  If a nanoparticle is taken up by a cell, size 
and shape can determine the cellular compartment to which the particle is trafficked 63. Local 
particle curvature also impacts the effective presentation of ligands to the targeted cell surface, 
depending on the contour of the cell membrane 50.  
2.4 Flexibility 
Nanomaterial scaffolds possess inherent rigidity or flexibility depending on their physical 
properties and shape (Figure 2c). Research suggests flexibility can also play a significant role in 
both in vivo transport and effective ligand presentation to cell surface receptors. Soluble, linear 
polymers can be flexible and can take on various molecular conformations. Therefore, the 
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orientation and spacing of ligands can be adapted to match the contour and receptor spacing of a 
given cell surface, which can be dynamic. In contrast, spherical or globular particles such as 
dendrimers, GNPs, liposomes, and proteins are inherently more rigid and have a more structured 
orientation and spacing of ligands 72,73. It follows that rigidity may play a role in cell receptor 
clustering, on both the number and proximity of receptors clustered together. In a ConA model 
receptor system, for example, clusters produced by linear polymers contained fewer receptors, 
but in proximity to each other, compared to clusters produced by globular protein conjugates of 
equal valency that contained more receptors spaced farther apart 30.  
Kobayashi et al explored the effects of rigidity in two different architectures of linear 
saccharide polymers for binding of surface lectins: poly(phenyl isocyanides) (PPI) which are 
rigid and helical, and phenyl acrylamides (PAP) which are flexible and extended. PAP showed 
significantly higher binding in both receptor systems, suggesting rigidity can inhibit binding to 
recognition elements on cell surfaces 74. In the context of colloids, flexibility has been reported 
to render a particle less likely to be phagocytosed by macrophages 50,75.  
Rigidity also affects the transport behavior of a particle in vivo, in particular the ability of 
a particle to flow through tortuous pathways and penetrate pores. Flexible particles can pass 
through pores that a spherical particle of equal size cannot 50,76,77. This plays a role in filtration 
through the liver and spleen and also permeability through extracellular space into tissues, 
thereby affecting clearance and delivery to target environments 50,72,73. 
Taken together, physical characteristics of nanomaterials are important considerations for 
the design of immunomodulatory nanomaterials.  The vast majority of clinical understanding is 
linked to a retrospective appreciation of nanomaterial properties of vaccines. A few research 
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endeavors have illuminated how nanomaterials may induce tolerance, including seminal work by 
Dintzis et al. 
 
3. Multivalent Ligand Display on Linear Polymers 
Given the historic properties of vaccines overlaid with our current understanding of 
nanomaterials, it is important to reconsider seminal research by Howard Dintzis and the latest 
developments in multivalent antigen delivery. The importance of multivalent antigen display for 
the ability of linear polymers to direct immune response was explored by Dintzis and others 
beginning in the late 1970s 78,79. Initially, Dintzis studied dinitrophenyl (DNP) antigenic ligands 
systematically grafted to linear acrylamide polymers of discrete molecular weight to assess their 
ability to evoke an immune response using a typical repeating polymeric template of a T cell 
independent antigen 80-86. In these early studies, Dintzis found that immune response in mice 
treated with the engineered multivalent polymers appeared to be driven by the antigenic ligand 
characteristics along the polymer backbone. 
Ligand valency and spacing, along with polymer size, were important nanomaterial 
parameters required to elicit specific immunological responses (Table 1). Specifically, Dintzis 
found that polymers less than 100 kDa were not immunogenic. However, size did not solely 
dictate an immune response, as large polymers without a sufficient number of conjugated 
antigenic ligands per molecule (low valency) failed to be immunogenic. Based on these 
observations, Dintzis hypothesized that a polymer of at least 100 kDa was required to evoke a 
strong immunogenic response. At this molecular weight, a polymer could theoretically 
accommodate at least 20 ligands approximately 100 Å apart, features Dintzis observed to provide 
a maximal immune response. They hypothesized a molecular mechanism whereby ligands 
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presented at this valency and spacing would create a threshold sufficient to bind and cluster a 
“minimum sized unit” of receptors on B cells and thus form an “immunon,” or a continuous 
cluster of ligands capable of initiating an immunogenic response 78 (Figure 3). 
Expanding upon his initial findings, Dintzis further explored the role of multivalent 
ligand display utilizing several different polymer backbones to evaluate immune response. In 
some of Dintzis’ earliest work, while he identified large polymers (>100 kDa) with sufficient 
valency as being immunogenic, Dintzis showed the cellular signaling caused by large 
immunogenic multivalent arrays could also be inhibited by administration of similar multivalent 
arrays of smaller size 82. Further investigation into these compounds revealed the smaller 
polymers of sufficient valency were not just inhibitory molecules, but rather induced long-term 
deficiencies to the immune response against the antigenic ligand. Specifically, he found that 
treatment of antigen-immunized mice with small polymers displaying multivalent antigenic 
ligand could repress the antibody response to the antigen. Furthermore, in a series of adoptive 
transfer experiments, Dintzis found the absence of immune response in animals treated with 
small multivalent molecules was B cell-dependent. Of importance, the antibody response to other 
antigens present at the time of immunization was not inhibited. This suggests 1) the small 
multivalent polymers could provide tolerance by specifically targeting a subset of antigen-
specific B cells, and 2) these multivalent polymers were not generally immunotoxic, thus 
avoiding global immunosuppression 84,87.  
More recently, Kiessling and others have sought to explain the ability of multivalent 
systems to elicit specific immune responses in vitro. They illustrated how structural features of a 
multivalent antigen array can cluster receptors, an essential determinant of B cell response. B cell 
receptor (BCR) clustering is important for signaling and B cell activation, directing the antigen-
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specific immune response towards immunity (clonal expansion and antibody production) or 
tolerance (clonal expansion, quiescence and/or cell death). Antigen avidity, dose, and valency 
can all affect response. Like Dintzis, Kiessling used linear polymer backbones of different 
lengths conjugated with DNP as a ‘hapten’ (i.e. small molecule antigen). Similar to Dintzis’ 
findings, Kiessling also found that increased valency led to increased antibody production in 
mice immunized with polymers of defined ligand density but variable valency (ligands per 
polymer) by varying the length of the final polymer. Multiple other studies have shown high 
valency is required to induce antibody production in vivo 78,88,89.  
Valency-dependence of signaling activity occurs in vitro, as evidenced by observations of 
B cell activation. In B cells treated with a defined molar concentration of DNP antigenic ligand, 
Kiessling found polymers of high valency (and size) had a greater capacity to induce calcium 
flux in DNP-sensitive B cells, suggesting polymers of increased valency and length have a 
higher capacity to activate B cells due to their ability to better cluster receptors. Interestingly, 
using this B cell system, Kiessling also observed a threshold at which increasing the dose of 
defined antigenic ligand-conjugated polymer no longer had a positive effect on signaling. This 
phenomenon was observed in vivo by both Snippe and Dintzis when looking at immune response 
as a function of antigenic ligand concentration 80,82,87,88,90-92. These studies suggest for a given 
polymer conjugated to antigenic ligand, signaling activity increases with ligand concentration as 
more receptors are clustered; however, at very high ligand concentrations where ligand is in 
great excess, ligands overwhelm the available binding sites and the resultant binding events favor 
formation of fewer receptors bound to each polymer complex. Discontinuous or incomplete 
binding of a single multivalent backbone may not facilitate the critical BCR clustering, which 
could account for the diminished immune response observed at very high ligand doses 34,43.  
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Kiessling further explored the importance of ligand density on the ability of a multivalent 
ligand to cluster receptors. Using concanavalin A (ConA) as a model receptor in an isolated 
system, Kiessling focused on three important aspects of receptor clustering: number of receptors 
in a cluster, rate of clustering, and receptor proximity. Upon comparing various multivalent 
architectures such as low molecular weight (MW) dimers and trimers, dendrimers, globular 
proteins, ROMP linear polymers of defined length, and high MW polydisperse linear polymers, 
Kiessling found that ROMP linear polymers favored receptor clustering over the other 
architectures. In particular, ROMP linear polymers formed tighter clusters of proximal receptors, 
especially compared to dendrimers and globular proteins 30.  
In general, there appeared to be a strong dependence of clustering on ligand density and 
valency across different scaffold architectures 30,41.  In mannose-conjugated linear polymers, the 
number of receptors in the cluster, rate of cluster formation, and receptor proximity increased as 
ligand density per polymer increased. It appeared low density arrays favored efficient receptor 
binding on a per ligand basis, while high density arrays favored greater total receptor binding per 
polymer array 41. Contrasting trends were observed in other receptor systems. In a DNP-
conjugated polymer system targeting the BCR, antigenic ligand density had negligible effect on 
signaling activity compared to total antigen valency and polymer length 34,43. Similarly, Minguet 
et al observed that bi- and trivalent soluble haptenated peptides triggered activation through BCR 
clustering in vitro but there was no effect of ligand spacing 42. As such, observations of 
tetrameric ConA clustering may not be an accurate reflection of clustering capabilities for all 
signal transduction pathways with other receptors (i.e. MHC, BCR, TCR, others). 
The dependence of receptor clustering on the structure of the target receptor has been 
illustrated in other studies 32. In a study using ConA as a model receptor, Kiessling observed the 
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ability of multivalent linear polymers with mannose ligand valencies ranging from 
approximately 20-140 to cluster ConA and subsequently aggregate T cells in vitro. Moderate 
valency (>20) was sufficient to complex and precipitate tetravalent ConA receptors, but high 
valency (>60) was required to complex and precipitate a bivalent form of ConA 93. The number 
of receptors clustered per polymer increased with increasing ligand valency. As before, Kiessling 
observed a threshold for the positive relationship between ligand concentration and clustering in 
both ConA systems, but a bell-shaped curve was only observed with increasing ligand 
concentration in the bivalent ConA system. This suggests the valency of both ligands and 
receptors are important for determining overall binding events. Thus, as clustering potential of 
multivalent ligands depends on both the nanomaterial and the targeted receptor system, 
nanomaterial design should perhaps be tailored according to the respective number, orientation, 
and spacing of epitopes in the target receptor 94. 
Overall, studies by Kiessling support the idea that high multivalent presentation of a 
single ligand type induces receptor clustering and localization, enables high levels of calcium 
signaling, and leads to upregulation of genes necessary for antibody production and an 
immunogenic response. In contrast, low valency produces low levels of calcium signaling that 
fail to trigger gene expression for antibody production, and are proposed to induce 
quiescence/apoptosis conducive to a tolerogenic response. This agrees with others who also 
observed a trend of tolerance induction using low molecular weight, low valency arrays, with the 
exception of Dintzis who also observed tolerance induction using low molecular weight, high 
valency arrays 34,79,84,95-97.  
Like Dintzis and Kiessling, Desaymard et al investigated multivalent DNP-conjugated 
linear polymers but used levan, dextran, pneumococcal polysaccharide, and D-glutamic acid/D-
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lysine (D-GL) copolymer as backbones. They observed similar density trends across all 
architectures, and found that antigen-specific tolerance could be induced in B cells with high 
valency polymers as evidenced by inhibition of antibody production 98. Tolerance induction to 
specific classes of immunoglobulins depended on antigenic ligand density. Their results partly 
contradicted Dintzis’ observations that nanomaterials under 100 kDa are not immunogenic: they 
found 20,000 kDa levan and 200 kDa dextran conjugates were immunogenic, while 70 kDa 
dextran conjugates were weakly immunogenic against the polymer but strongly immunogenic 
against the antigen. Other observations with the D-GL copolymer align with Dintzis’ theory that 
nanomaterials with a valency >20 and density >10 antigens/50 kDa are immunogenic if 
MW>100 kDa, but tolerogenic if MW<100 kDa. The D-GL copolymer, containing a high 
antigen density of 37 antigen/50 kDa and a MW below the 100 kDa threshold, was observed to 
be strongly tolerogenic. The high density D-GL conjugates were tolerogenic regardless of dose 
in vitro, but lower density conjugates were immunogenic at low antigen dose and inhibitory at 
high antigen dose. A bell-shaped dose-response curve was observed with the immunogenic levan 
and dextran conjugates 99,100. These contradictory results highlight the complex interplay of 
nanomaterial physical properties and structural components in multivalent systems. 
Dintzis’ work provided strong and convincing evidence that polymeric antigen arrays can 
provide selective immune stimulation. Furthermore, this work is some of the first to suggest 
immunological memory can be reversed depending upon the context of subsequent antigen 
delivery. A simplistic explanation for Dintzis’ observations is that small multivalent arrays may 
inhibit the proposed (approximate) 20-BCR cluster threshold required for B cell activation, 
leading to an anergic response by the targeted cell(s). Recently, other multivalent systems such 
as autoantigen-conjugated poly(lactic-co-glycolic acid) (PLGA) and polystyrene (PS) 
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nanoparticles have been observed to mediate tolerance in autoimmune disease 101,102. 
Experiments conducted with various polymeric nanomaterials suggest these constructs work in 
large part due to their ability to occupy or divert immune cells (i.e. decoy mechanism) rather than 
induce anergy or any kind of lasting tolerance 103. For example, some studies suggest multivalent 
polymers may function in part through their ability to coat the cell and sterically inhibit 
competitive binding, thereby inhibiting cell-cell interactions by creating a hydrophilic, swollen 
gel layer that coats the cell surface 104. Whether these molecules specifically delete or simply 
inhibit antigen-sensitive clones has yet to be determined. In other studies by Dintzis utilizing 
polymers of similar size and valency, he observed polymers in splenic tissue were associated 
with a pattern that suggested interaction with dendritic cells 83. However, more studies are 
required to elucidate whether dendritic cells can be specifically targeted by multivalent 
polymeric arrays and whether true tolerance can be induced by multivalent display of other 
ligand types.  
 
4. Multivalent Display of Two Different Ligands on Linear Polymers 
Hetero-ligand presentation, which is the display of two or more signals, on linear 
polymers has also been investigated for directing immune response (Figure 4a). A summary of 
various multivalent linear polymer systems with either one or two signals may be viewed in 
Table 2. In addition to the primary antigen, inclusion of an ancillary signal may contribute to the 
overall specific or nonspecific binding of multivalent nanomaterials, as well as influence 
response. Secondary signals can drive both molecular conformation and the final effect of the 
antigen by directing or enhancing its response 32. For example, Whitesides et al incorporated a 
secondary ligand into sialic acid-bearing polyacrylamide arrays to inhibit influenza viral 
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adhesion to erythrocytes. Inhibition by multivalent arrays greatly exceeded that of the monomer 
equivalent, and was further improved by the addition of secondary functional groups. 
Hydrophobic and aromatic secondary ligands were especially effective, perhaps due to the 
binding of hydrophobic sites on the cell surface to sterically block virus attachment 104. In other 
cases, secondary ligands have been added to enhance 105, suppress 106,107, or shift the cellular 
response 108.  
Using her original DNP-displaying polymer, Kiessling et al developed a series of homo- 
and hetero-ligand multivalent (250 unit) polymers conjugated with DNP and a ligand for CD22 
(CD22L). DNP antigenic homo-polymer containing ~83 DNP, CD22L co-receptor homo-
polymer containing ~58 CD22L, and DNP/CD22L copolymer containing ~90 DNP and 60 
CD22L were studied. Treatment of B cells expressing DNP-specific BCRs with a multivalent 
hetero-polymer displaying both DNP antigenic ligand and CD22L exhibited reduced cell 
signaling and suppressed B cell activation, due to the molecule’s ability to interact 
simultaneously with both the BCR and CD22. Several other groups have made similar findings 
107,109,110 suggesting co-presentation of antigen and CD22L on either polymers or liposomes can 
reduce B cell-dependent immune responses. Interestingly, the reduced B cell-dependent immune 
response in mice treated with liposomes co-presenting antigen and inhibitory CD22L was 
associated with an increase in B cell apoptosis. B cell responses to other antigens were not 
affected, suggesting these molecules were not overtly immunotoxic to all B cells. Inclusion of an 
appropriate secondary ligand was critical for reducing an antigen-specific immune response. 
Furthermore, addition of targeting and inhibitory ligands on immunomodulatory nanomaterials 
may be a potential avenue to specifically delete antigen-sensitive B cell clones, which has 
significant implications in autoimmune disease and immune hypersensitivity 111. 
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More recently, Sestak et al employed a similar strategy, co-delivering antigenic ligand 
and immune inhibitor by developing a multivalent hetero-ligand polymer to reverse disease in 
experimental autoimmune encephalomyelitis (EAE), the murine model of multiple sclerosis 
108,112. Sestak utilized small hyaluronic acid polymers (16 kDa, HA) complexed with a disease-
specific autoantigen (proteolipid protein peptide epitope, PLP139-151) and a peptide ligand 
(LABL) that binds intracellular cell-adhesion molecule-1 (ICAM-1). ICAM-1 contributes to 
immune cell adhesion 113-115 and costimulation of the immune response 116-118. Co-delivery of 
antigenic peptide and LABL peptide in a multivalent array was significantly more effective in 
reducing disease compared to a mixture of the free components (HA, PLP, LABL) or homo-
polymers containing either PLP or LABL. Interestingly, delivery of a mixture of the two homo-
polymers (PLP homo-polymer and LABL homo-polymer) was sufficient to repress disease in 
EAE mice. Adaptation of this technology utilizing multivalent hetero-ligands of antigen (PLP) 
and peptides that bind immune cell surface receptors (CD80 and CD86) has also been effective 
at reducing disease in EAE mice 119.  
GNP vaccine research suggests inclusion of a secondary ligand can be used to activate 
additional cell subsets that would not typically be targeted by antigen, such as Th2 49,105,120 or 
Treg 121. For example, T-helper peptide (molecular adjuvant) can be delivered alongside B cell 
carbohydrate antigen to trigger a robust T-helper response and prolong immunological memory 
105. In these studies, a specific ratio of antigen, molecular adjuvant, and spacer ligand (45:5:50) 
was necessary to induce a strong Th2-aided antigen-specific response. Thus, when multiple 
ligand types are presented, their ratio may be important for eliciting a specific and robust 
response. This ratio appears to vary for different immunogenic nanomaterials and may be 
dependent upon the intrinsic affinity of the ligand, but observations by Kiessling, Duong, and 
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Sestak suggest an approximate ratio of 1:1 antigenic ligand to co-receptor ligand is able to elicit 
a tolerogenic response 106-108,112. 
Studies with nanomaterials other than linear polymers suggest co-delivery of two signals 
on the same backbone is critical for inducing an immune response 49,105,121. Hassane et al found 
that incorporation of B cell epitope and Th epitope ligands onto the same liposome was 
necessary to promote BCR clustering, B cell activation, and immune protection 49. Hence, it is 
necessary to consider co-delivery of antigen and molecular adjuvant in the same spatial and 
temporal context. Similarly, co-presentation of antigen and CD22 ligands on liposomes was 
required to inhibit B cell signaling 122. In linear polymers, there are mixed indications as to 
whether co-delivery of multiple signals on the same backbone enhances the resultant immune 
response. Kiessling et al observed that co-presentation of a CD22 ligand alongside antigen on the 
same linear polymer backbone was necessary to suppress antigen-specific B cell activation, 
whereas delivery of a mixture of antigen- and CD22L-homo-polymers was not sufficient to 
reduce B cell activation 106. In contrast, Sestak et al observed similar therapeutic efficacy in EAE 
from treating mice with a copolymer presenting both antigen and cell adhesion inhibitory 
peptides (PLP and LABL) versus a mixture of homo-polymers presenting either antigen (PLP) or 
inhibitor peptide (LABL) 112. Sestak’s work may suggest that co-presentation of multiple ligand 
types on separate, flexible, linear polymers may be sufficient when blocking cell adhesion 
molecules to inhibit immune response.  
One hypothesis for efficacy upon delivering a mixture of homo-polymers is the potential 
for interactions between the side chains and backbones of neighboring molecules which could 
allow for accidental “bystander” entanglement of homo-polymers, effectively co-delivering the 
two signals (Figure 4b). Indeed, work by Dintzis suggested very large flexible polymers with 
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appropriate valency, but large (inappropriate) spacing between ligands, could be immunogenic 
due to conformational rearrangement of the polymer (Figure 3cd). Such flexibility could 
theoretically decrease the “effective” spacing between ligands in a folded polymer to the 
proposed ideal ~100 Å spacing required to elicit a full immune response 78. This is not the case 
for rigid scaffolds and particles, which cannot intimately interact with neighboring molecules 
due to the rigidity of the material and set organization and orientation of ligands, that is unless 
very long flexible linkers are employed (Figure 4). 
In Kiessling’s case the hetero-polymer suppressed BCR activation due to its ability to 
interact with proximal receptors (BCR and CD22) on the same B cell surface in a purified B cell 
system. Thus, co-presentation of ligands on a single polymer with controlled ligand spacing may 
be required for targeting the cell surface to accommodate receptors in proximity. In contrast, 
Sestak’s observations were based in an animal model (EAE) requiring B cells, T cells and other 
immune cells such as dendritic cells to establish disease. As alluded to above, some of Dintzis’ 
work suggested multivalent polymers could directly interact with dendritic cells. Taken together, 
this may indicate that at least for some antigenic ligands, delivery of two independent homo-
polymers can effectively deliver two signals in the same time and space. The mechanisms 
whereby homo-ligand polymer pairs and hetero-ligand polymers tailor immune response require 
further investigation.   
 
5. Proposed Mechanisms for Immune Response to Multivalent Nanomaterials 
Similar to the colloidal adjuvants used in traditional vaccines, the physical carrier and 
delivery system of multivalent nanomaterials is an important aspect of the design of safe and 
efficacious antigen-specific immunomodulators. Nanomaterial science brings a large, diverse 
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library of carrier molecules to the fields of vaccines and immunotherapy. The physical and 
chemical characteristics of each independent nanomaterial component must be carefully chosen. 
Not only do size, shape, rigidity, and chemistry determine the transport fate of a compound, 
which consequently determines immune exposure, but these properties can direct and amplify 
immune response. Importantly, the structure of the nanomaterial and conjugation to available 
functional groups will determine ligand valency and density, both having a direct impact on 
immunological outcome.  
Although the exact molecular mechanisms for how ligand valency and density affect 
immune response have yet to be resolved, much of the work by Dintzis, Kiessling, and other 
researchers are in agreement that these principles heavily weight the resultant immune response. 
While Dintzis and Kiessling showed large flexible polymers meeting some minimum valency 
and density criteria may be prime candidates to evoke a protective prophylactic immune 
response, Dintzis found small polymers (<100 kDa) may actually induce a long-term antigen-
specific immune deficit, or tolerance, towards a given antigen. The studies reviewed here 
highlight the complex interplay of physical properties in multivalent nanomaterials, and also 
reflect the complexity of antigenic immune response. For instance, while it is known that co-
receptor engagement may direct the polarity of a response towards immunogenicity or tolerance 
123,124, it is less well understood when antigen receptor engagement alone will induce either 
immunogenicity or tolerance. It may be driven by the degree of receptor engagement, clustering, 
and cross-linking, such that highly cross-linked receptors produce an immunogenic response 
while poorly cross-linked receptors produce tolerance 78,84,125. Dintzis’ ‘immunon hypothesis’ 
and Kiessling’s studies with receptor clustering support this idea. Other studies suggest antigen 
response may be driven by dose.  
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Desaymard observed an interesting dose-dependent response by high density copolymer 
conjugates, which elicited an immunogenic response at low antigen dose and a tolerogenic 
response at high antigen dose 100. However, there is more agreement among Dintzis, Kiessling, 
and Desaymard regarding a “bell-shaped” dose response curve to immunogenic multivalent 
polymers in which both high and low doses fail to promote an immune response. Since long-
term, low antigen exposure is utilized for allergic hyposensitization treatment, it would be 
interesting to test whether low, sub-optimally stimulating doses of multivalent polymers could 
actually induce tolerance over time 126,127. Conversely, as high antigen doses can induce clonal 
deletion or anergy in lymphocytes 128,129, would extremely high doses of multivalent polymers 
induce a robust tolerogenic effect as well? Future studies can explore these possibilities in both 
multivalent polymers and other nanomaterial systems. Additionally, further investigation is 
needed to establish a set of rules about physical parameters of multivalent soluble, linear 
polymers that elicit either an immunogenic or tolerogenic response, as Dintzis proposed, 
especially when treating larger mammals and humans. Seminal work by Dintzis may be 
illuminated by the advanced tools available today for characterizing nanomaterials.  
As discussed, Dintzis and Kiessling have heavily investigated the molecular 
mechanisms enacted by multivalent soluble, linear polymers in order to direct an immune 
response (Figure 3). Dintzis established the ‘immunon hypothesis’ and proposed multivalent 
nanomaterial parameters (length, valency, and spacing) that lead to an immunogenic versus 
tolerogenic response. In support of a molecular mechanism, Kiessling has shown that multivalent 
ligands influence cell surface receptor clustering, signal transduction, and immune activation in 
vitro. Kiessling and others have also shown that secondary ligands, in addition to antigen, may 
contribute to overall binding, costimulation or inhibition of signaling, and augmentation of 
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immune response.  The idea that multivalent nanomaterials enact an immune response through a 
molecular mechanism has been well established.  
However, there have been some discrepancies between studies, in particular studies by 
Kiessling and Dintzis relating to a threshold polymer length and antigenic ligand valency 
required to elicit immunogenicity. These discrepancies, and some of our current lack of 
understanding surrounding the immunomodulatory abilities of nanomaterials, may be attributed 
to a deficiency in transport and pharmacokinetic observations with these systems. For example, 
many of Kiessling’s studies were performed with B cells in vitro, bypassing any transport step, 
whereas Dintzis observed responses to nanomaterials delivered in vivo (often after 
intraperitoneal administration), which were affected by transport and exposure to additional 
immune cell subsets such as phagocytes and T cells. In another case, Desaymard observed 
contrasting results with high-density copolymers that were exclusively tolerogenic regardless of 
dose in vitro but not in vivo 99,100. Therefore, a transport mechanism must also play a key role 
in the way a multivalent nanomaterial enacts an immune response (Figure 5). 
Local transport and pharmacokinetic considerations are critically linked to the molecular 
interactions that lead to immune response, especially in the nanomaterial arena where there is a 
large, diverse library of carrier molecules. For instance, adjuvants used in vaccines are typically 
colloids comprised of relatively rigid particles, which encourage depot formation at the injection 
site and recruitment of APCs. In contrast, soluble, linear polymers are flexible and may be more 
prone to diffuse throughout the tissue and even into systemic or lymphatic circulation, 
potentiating a fundamentally different immune response than colloidal depot systems (Figure 5). 
Specifically, smaller, soluble, linear polymers may bypass peripheral immune activation by quiet 
drainage to secondary lymphoid organs and therefore favor tolerance induction. Thus, delivery 
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and subsequent transport of a therapeutic nanomaterial should be considered during design and 
study. 
Transport of antigen to the lymphatic system is thought to be a vital component of the 
immune response and may offer insight into the different immunological effects of 
nanomaterials. Lymph nodes provide discrete immunological environments with specific cell 
populations sequestered in a very highly structured architecture that can facilitate immune 
response 130,131. A nanomaterial designed to initiate an immune response may be delivered to the 
lymphatics through a much different route compared to one intended to induce tolerance, as 
mentioned above. Classic routes of administration such as subcutaneous, intramuscular, and 
intravenous injection depend on different methods of antigen transport. Subcutaneous delivery 
may utilize both passive and active transport to the lymphatic system, as the antigen can either 
diffuse from the site of injection or be carried by peripheral macrophages to the lymph node 132. 
Intramuscular delivery may be more likely to form a depot at the site of injection, such that 
recognition in the periphery and active transport by immune cells is the likely mechanism of 
transport to the lymphatics. Intravenous delivery is typically used to systemically deliver the 
injectable, in which case the antigen can be taken up by circulating immune cells in the blood 
and directed to the liver or spleen 133. Since clearance of the antigen from blood circulation can 
occur at an accelerated rate, a complete immunological response may not take place 134.  
In addition to these classic routes, direct intranodal injection of antigen was recently 
explored for hyposensitization therapy. While traditional methods to promote hyposensitization 
toward specific allergens required multiple subcutaneous injections of allergen at low 
concentration over the course of years, recent clinical trials demonstrated injection of the 
allergen directly into the lymph nodes resulted in more rapid hyposensitization toward the 
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allergen, requiring fewer injections 131-132,135-137. Similarly, intranodal injection of colloidal or 
particulate systems that are traditionally immunogenic may actually induce tolerance, perhaps by 
bypassing peripheral recognition mechanisms and activation. Striking differences in immune 
response when changing the injection site underscore the importance of the transport and 
pharmacokinetics of nanomaterial vaccines and immunotherapies. 
 
6. Conclusions and Future Directions 
The diversity and continued development of nanomaterials have provided many 
opportunities for improving immunomodulatory therapies. Vaccinologists have long known that 
non-immunogenic epitopes make for poor prophylactic vaccine candidates and therefore have 
added adjuvants to boost their efficacy. Several examples outlined within this review illustrate 
how multivalent nanomaterials may provide a stepping-stone in the evolution of vaccines. For 
instance, the selection of an intrinsically immunogenic nanomaterial scaffold may itself act as a 
molecular adjuvant while also improving binding avidity and antigen-specificity through 
multivalent presentation of antigen. Additionally, co-presentation of a secondary ligand as a 
molecular adjuvant on the nanomaterial scaffold can direct or boost the immune response 
towards a given antigen. For these reasons, multivalent nanomaterials may be suitable for future 
prophylactic vaccine design and formulation.  
Multivalent nanomaterials have also evolved for applications where immune tolerance is 
desired, such as autoimmune diseases or allergies. As research dating back to Howard Dintzis 
suggests, modulating polymer length, antigenic ligand valency, and antigenic ligand density may 
enable a nanomaterial to induce tolerance instead of immunogenicity. Using principles of 
molecular adjuvants, new research has emerged suggesting co-delivery of a secondary signal can 
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also promote a tolerogenic response to a given antigen, although the proposed mechanisms of 
tolerance induction vary widely. Ligand display and other physical properties of multivalent 
nanomaterials play a role not only in a molecular mechanism for immune response, such as the 
classic ‘immunon hypothesis’, but also in a transport mechanism for biodistribution. We propose 
both mechanisms are important considerations for nanomaterial design, and necessary for 
advancements in antigen-specific immunotherapies for autoimmune diseases. Creation of 
antigen-specific tolerogenic therapies in humans would be groundbreaking, reducing or 
eliminating the risk of global immunosuppression. 
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Table 1. Dintzis’ Rules 
MW (kDa) Valency  (# Haptens/Molecule) Immunogenicity Tolerogenicity 
>100 kDa 
>20 Increases with valency - 
<20 - - 
<100 kDa 
>20 - High 
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Table 2. Summary of Multivalent Linear Polymer Systems. 
Polymer Signal 1 Signal 2 Valency Size Immune Response Ref. 
Polyacrylamide 
Dinitrophenol   38 360 kDa Immunogenic 74 
Dinitrophenol 
 
53 145 kDa Immunogenic 74 
Dinitrophenol 
 
59 460 kDa Immunogenic 74 
Dinitrophenol 
 
97 460 kDa Immunogenic 74 
Dinitrophenol 
 
126 430 kDa Immunogenic 74 
Dinitrophenol 
 
17 330 kDa Immunogenic 72 
Dinitrophenol 
 
48 140 kDa Immunogenic 72 
Dinitrophenol 
 
66 180 kDa Immunogenic 72 
Dinitrophenol 
 
20 380 kDa Immunogenic 81 
Dinitrophenol 
 
38 360 kDa Immunogenic 81 
Dinitrophenol 
 
53 145 kDa Immunogenic 81 
Dinitrophenol 
 
59 460 kDa Immunogenic 81 
Dinitrophenol 
 
97 460 kDa Immunogenic 81 
Dinitrophenol 
 
126 430 kDa Immunogenic 81 
Dinitrophenol Siglec-G ligand 200 1,000 kDa Tolerogenic 101 
Dinitrophenol CD22 400 1,000 kDa Tolerogenic 101 
Dinitrophenol 
 
19 60 kDa Other 74 
Dinitrophenol 
 
20 380 kDa Other 74 
Dinitrophenol 
 
19 60 kDa Other 82 
Dinitrophenol 
 
43 130 kDa Other 82 
Dinitrophenol 
 
8 130 kDa Other 72 
Dinitrophenol 
 
14 50 kDa Other 72 
Dinitrophenol 
 
25 80 kDa Other 72 
Dinitrophenol 
 
2 350 kDa Other 81 
Dinitrophenol 
 
3 350 kDa Other 81 
Dinitrophenol 
 
4 350 kDa Other 81 
Dinitrophenol 
 
6 350 kDa Other 81 
Dinitrophenol 
 
7 350 kDa Other 81 
Dinitrophenol 
 
10 350 kDa Other 81 
Dinitrophenol 
 
11 40 kDa Other 81 
Dinitrophenol 
 
19 60 kDa Other 81 
Fluorescein 
 
95 300 kDa Immunogenic 90 
Fluorescein 
 
230 400 kDa Immunogenic 90 
Fluorescein  150 630 kDa Immunogenic 76 
Fluorescein 
 
12 53 kDa Other 76 
Fluorescein 
 
340 600 kDa Other 75 
Fluorescein 
 
21 40 kDa Other 75 
Fluorescein   47 80 kDa Other 90 
Dextran 
Fluorescein   65 400 kDa Immunogenic 90 
Fluorescein 
 
60 170 kDa Immunogenic 90 
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Fluorescein 
 
960 2,300 kDa Immunogenic 76 
Fluorescein 
 
3600 10,000 kDa Immunogenic 76 
Fluorescein 
 
7 30 kDa Immunogenic 77 
Fluorescein 
 
35 100 kDa Immunogenic 77 
Fluorescein 
 
150 500 kDa Immunogenic 77 
Fluorescein 
 
30 70 kDa Tolerogenic 89 
Fluorescein 
 
8 21 kDa Tolerogenic 76 
Fluorescein 
 
7 30 kDa Tolerogenic 78 
Fluorescein 
 
14 40 kDa Other 90 




15 30 kDa Tolerogenic 78 






8 - 10% 100-mer Immunogenic 28 
Dinitrophenol 
 
8 - 10% 250-mer Immunogenic 28 
Dinitrophenol 
 
8 - 10% 500-mer Immunogenic 28 
Dinitrophenol CD22 ligand 33 - 36% 250-mer Tolerogenic 100 
Mannose 
 
100% 143-mer Other 35 
Mannose 
 
71% 145-mer Other 35 
Mannose 
 
45% 115-m34 Other 35 
Mannose 
 
31% 86-mer Other 35 
Mannose 
 
18% 102-mer Other 35 
Mannose 
 
10% 116-mer Other 35 
Mannose 
 








































Fluorescein   240 750 kDa Immunogenic 90 
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38 16.9 kDa Tolerogenic 102 
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Figure 1. Nanomaterial architectures: a) linear polymers of different lengths, b) liposome, c) 2nd 
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Figure 2. Important multivalent nanomaterial properties: a) ligand valency of 8 and 16 for 
different nanomaterials; b) ligand density; c) variations in rigidity between linear polymers and 
spherical particles. The spacing of ligands on a linear polymers is variable due to multiple 
conformations of the polymer chain, while the ligands on a rigid sphere are relatively fixed in 
spacing and orientation, even when utilizing flexible linkers. 
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Figure 3. Molecular mechanism for multivalent linear polymers: Polymers must be of sufficient 
length, ligand valency, and ligand density to adequately cluster cell surface receptors for signal 
transduction. Potential signaling outcomes of multivalent linear polymers with a) insufficient 
length and/or insufficient valency, b) inappropriate spacing, c) inappropriate length and spacing, 
d) appropriate ‘functional’ spacing due to secondary structure after conformation change, and e) 
appropriate spacing and sufficient valency. 
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Figure 4. Co-delivery of primary signal (antigen) and secondary signal (molecular adjuvant, 
costimulatory signal, co-receptor ligand): a) co-delivery on different nanomaterial backbones, b) 
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Figure 5. Potential transport mechanisms for multivalent nanomaterials: Soluble, flexible, linear 
polymers are prone to passively drain into systemic or lymphatic circulation, depending on size. 
Multivalent modification with antigen and tolerogenic adjuvant, in conjunction with quiet 
drainage to the lymph, may promote an antigen-specific tolerogenic response and lasting 
regulatory memory. Conversely, rigid colloidal particles are prone to form a depot at the 
injection site, attracting APCs for active transport into the lymph. Multivalent modification with 
a high density of antigen and classic adjuvant, in conjunction with active transport to the lymph, 
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Chapter II: Molecular Dynamics of Multivalent Soluble 
Antigen Arrays Support Two-Signal Co-delivery Mechanism 
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1. Introduction 
Many autoimmune disorders are triggered by the immune system’s misrecognition of self 
versus non-self epitopes, an event hypothesized to promote autoreactive T cell and/or B cell 
clonal expansion and attack against self-antigen(s). Many current therapies for patients with an 
autoimmune disease cause global immunosuppression, introducing risk of serious adverse side 
effects. 1-3 As a result, there is a strong interest in designing therapeutic agents to shift the 
autoreactive immune response towards tolerance of specific autoantigens. 4, 5 Multivalent antigen 
arrays, composed of antigen and an inhibitor co-grafted to a flexible polymer backbone (Table 
1), are hypothesized to induce antigen-specific tolerance and thereby obviate the need for global 
immunosuppression. 6-9 These arrays have emerged as a promising option with potential to 
induce an antigen-specific immune response to repress autoimmune disease. 10, 11  
Studies dating back to the 1970s have shown that polymeric multivalent antigen array 
physical characteristics such as antigen valency, density, and polymer molecular weight may be 
tailored to induce immune tolerance. 6, 7, 12-15 The ability of these antigen arrays to modulate 
immune response may be explained in part by a cellular mechanism, whereby the appropriate 
physical presentation of multivalent antigen enables sufficient cell receptor clustering, 
engagement, and/or initiation of a tolerogenic cellular response. 16-20 Leveraging antigen-
specificity and desired physical characteristics, multivalent antigen arrays could potentially guide 
the immune response to the conjugated antigen.  
Previously, our group developed a multivalent soluble antigen array (SAgA) for the 
treatment of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple 
sclerosis (MS). 21, 22 A SAgA molecule consists of a linear hyaluronic acid (HA) polymer 
backbone co-grafted with both myelin sheath antigenic peptide (proteolipid protein peptide, 
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PLP139-151) and intercellular adhesion molecule-1 (ICAM-1) inhibitor peptide, LABL, derived 
from leukocyte function associated antigen-1 (LFA-1). SAgA co-presentation of two signals 
(PLP and LABL) seeks to exploit immunology dogma that says the presence of two signals, both 
primary antigen and secondary costimulatory or inhibitory signal, is especially effective and 
sometimes necessary for eliciting a robust immune response. 10, 11, 23 The secondary signal may 
be costimulatory or inhibitory, acting as a context signal to direct the immune response towards 
the primary antigen. 18, 24, 25 For example, the autoreactive myelin-specific T cell attack in MS is 
propagated by the immunological synapse between antigen presenting cells (APCs) and T cells, a 
signaling event which requires both a primary antigen-specific signal and a secondary signal. 26-
32 In other cases, it’s been shown that engaging the B cell receptor along with an inhibitory 
coreceptor inhibits B cell activation, 33 while co-delivery of a B cell epitope and T helper cell 
epitope induces antigenic protection. 34 SAgA molecules, by presenting autoantigen and 
secondary inhibitory signal on a polymer backbone, may target and interrupt antigen-specific 
signaling by APCs such as dendritic cells or B cells. 35 LABL may block immune cell adhesion, 
thereby inhibiting autoreactive T cell and/or B cell clonal expansion to redirect the immune 
response towards autoantigenic tolerance. 36, 37 We propose that co-presentation of both primary 
and secondary signals in the same spatial and temporal context must occur for therapeutic 
efficacy (i.e. coincident two-signal co-delivery). 
Various methods were employed to probe the mechanism of SAgA molecules and the 
properties that render them therapeutic. In silico molecular dynamics simulations were used to 
predict molecular conformation and conformational stability to further understand SAgA 
behavior on a molecular level under physiological conditions. Particle size was determined by 
dynamic light scattering to clarify particle transport behavior. EAE animal studies were 
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performed to assess the therapeutic efficacy of SAgA molecules compared to arrays of different 
design or composition. These studies were used to elucidate the role of two-signal co-delivery in 
determining therapeutic potential. By gaining a greater understanding of these molecules’ 
properties and mode of action, we can refine the design criteria needed to better develop 
autoantigen-specific therapeutic agents to treat autoimmune disease.  
 
2. Materials and Methods 
2.1 Materials 
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN). Aminooxy-LABL (AoLABL, Aoa-itDGEATDSG-OH) and 
aminooxy-PLP (AoPLP, Aoa-HSLGKWLGHPDKF-OH) were purchased from PolyPeptide 
Laboratories (San Diego, CA). Incomplete Freund’s adjuvant (IFA) and killed Mycobacterium 
tuberculosis strain H37RA were purchased from Difco (Sparks, MD). Pertussis toxin was 
purchased from List Biological Laboratories (Campbell, CA). All other chemicals and reagents 
were analytical grade and used as received.  
2.2 Preparation and Characterization of Soluble Antigen Arrays 
Synthesis of SAgAs was described previously. 21 Aminooxy peptides AoLABL and/or 
AoPLP were reacted with 2 mg/ml HA by briefly dissolving in 20 mM acetate buffer (pH 
adjusted to 5.5±0.1) then stirring at 500 rpm for 24 hours at room temperature. The reaction 
solution was dialyzed (MWCO 6000-8000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, 
CA) against 100X the reaction volume of deionized water and rinsed four times over 24 hours to 
remove unreacted free peptides and salts. Dialyzed samples were then frozen and lyophilized.  
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Peptide conjugation was determined through gradient reverse-phase analytical high-
performance liquid chromatography (RP-HPLC) (Waters Corp., Milford, MA) on a C18 
analytical column (Higgins Analytical, Proto200, 5 µm, 200 Å, 250 x 4.6 mm2, Mountain View, 
CA), following cleavage of peptides in 0.1N HCl. Samples were compared to standard curves of 
AoPLP and AoLABL to determine peptide content. A gradient method with aqueous mobile 
phase A (94.9% d.d. H2O, 5% acetonitrile, 0.1% trifluoroacetic acid (TFA)) and organic mobile 
phase B (99.9% acetonitrile, 0.1% TFA) was used to analyze samples. Samples were detected at 
220 nm. 
2.3 Particle Characterization by Dynamic Light Scattering 
The size distribution of particles was evaluated using dynamic light scattering (Zeta-
PALS, Brookhaven Instrument Corp., Holtsville, NY) measured at 90¹ and operated at 658 nm 
and 25¹C. Hydrodynamic radius (Rh) was determined from the Stokes-Einstein equation: 
    𝑅! =
!!!
!!"!!
     (Equation 1)  
where kb is the Boltzmann’s constant, T is temperature (K), η is the solvent viscosity, and DT is 
the translational diffusion coefficient. Particle size was reported as hydrodynamic diameter, Dh, 
where Dh = 2×Rh. Samples were measured (n=5) in phosphate-buffered saline (PBS, 0.137 M 
NaCl, pH 7.4) at ambient temperature after passing through a 0.45 µm PVDF filter. The particle 
size distribution was derived from the autocorrelation function using a non-negatively 
constrained least squares (NNLS) deconvolution algorithm. 
Particle size of HA and SAgAPLP:LABL (SAgA reacted with PLP and LABL) was first 
investigated as a function of sample molarity varying from 0.0134 to 0.428 mM in order to 
determine an appropriate concentration for further DLS characterization. All samples were then 
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characterized by DLS at a concentration of 0.0625 mM. In addition, HA particle size was 
observed in 0.1M ammonium acetate buffer (pH 5.0±0.1) as a function of salt concentration 
varying from 0.01 M to 1.0 M sodium chloride (NaCl) to observe aggregation behavior of 
molecules.  
2.4 Clinical EAE Study in Mice 
Animal studies were carried out with 4-6 week old SJL/J (H-2) female mice purchased 
from Harlan Laboratories (Indianapolis, IN). Mice were housed under specified, pathogen-free 
conditions at The University of Kansas and all experiments were approved by the University’s 
Institutional Animal Care and Use Committee. Complete Freund’s adjuvant (CFA) was made by 
combining IFA and killed M. tuberculosis strain H37RA at a final concentration of 4 mg/ml. 
Animals were induced with experimental autoimmune encephalomyelitis (EAE), the PLP-
specific mouse model of relapsing-remitting MS, on day 0 of the study. Immunization was 
accomplished using a 0.2 ml emulsion containing 200 µg PLP139-151 peptide, plus equal volumes 
of PBS and CFA. The emulsion was administered subcutaneously (s.c.) as a total of four 50 µl 
injections, located above each shoulder and each hind flank. Pertussis toxin (100 ng in 100 µl) 
was injected intraperitoneally on day 0 and day 2 post-immunization. 
Treatments were administered on days 4, 7, and 10 as 100 µl subcutaneous injections at 
the nape of the neck (n=6 mice per treatment group). Samples and vehicle control (sterile PBS) 
were administered at a dose equivalent to 200 nmol PLP per 100 µl (2 mM PLP). This schedule 
and dose were found to be efficacious in a previous study. 22 HALABL (SAgA containing LABL) 
was dosed at an equivalent LABL concentration (2 mM LABL) and HA was dosed at an 
equivalent SAgA concentration (0.214 mM). Disease progression was evaluated by a single 
observer using the following clinical score system: 0, no clinical disease symptoms; 1, weakness 
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or limpness of the tail; 2, weakness or partial paralysis of one or two hind limbs (paraparesis); 3, 
full paralysis of both hind limbs (paraplegia); 4, paraplegia plus weakness or paralysis of 
forelimbs; 5, moribund (at which point mice were euthanized). In addition to animal scoring, 
body weight measurements were performed daily for the 26-day duration of the EAE study. 
2.5 Molecular Dynamics Simulations of Soluble Antigen Arrays 
Molecular dynamics simulations were used to computationally simulate the physical 
forces acting on SAgAs and other molecules in order to evaluate their conformations over time 
scales of 20-40 ns. Several molecule configurations were simulated: 
1. HA: One 16 kDa HA polymer backbone. 
2. HALABL: One 16 kDa HA backbone with 20 side chains of LABL spaced equally along the 
backbone. 
3. HAPLP: One 16 kDa HA backbone with 20 side chains of PLP spaced equally along the 
backbone. 
4. SAgAPLP:LABL: One 16 kDa HA backbone with 10 side chains of PLP and 10 side chains of 
LABL, alternately spaced at equal distances along the backbone. 
5. Homopolymer mixture: One full-length HALABL molecule as in (2) and one full-length 
HAPLP molecule as in (3) placed side-by-side. 
6. SAgA component mixture: One 16 kDa HA polymer backbone with 10 free PLP and 10 free 
LABL peptides. 
7. Peptide mixture: Eight free PLP and eight free LABL peptides placed in a cube arrangement. 
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8. Heteropolymer mixture: Two full-length SAgAPLP:LABL molecules as in (4) placed side-by-
side. 
The molecular dynamics simulations were performed using Desmond software. 38 The 
molecular systems were prepared for simulation and solvated using a single-point-charge (SPC) 
model. Further, Na+ and Cl- ions were added to the system at a 0.15 M concentration in order to 
simulate physiological conditions. The force field used for simulations was OPLS2005 as 
available in Desmond. 39 The default system relaxation protocol was used to equilibrate the 
simulation systems prior to production simulation. An NPT (isothermal-isobaric) ensemble was 
then used in the production simulations, with constant temperature of 27°C (300K) and constant 
pressure of 1 atm (1.01325 bar). Production simulations were run for a total of 20-40 ns. The 
Nose-Hoover thermostat was used to control temperature, 40 and the Martyna-Tobias-Klein 
barostat was used to control pressure. 41 Coulombic interactions were calculated using the Ewald 
smooth particle-mesh approach. 42 The RESPA integrator was used with 2 fs time step intervals 
for bonded/non-bonded interactions at short ranges, and a 6 fs step was used for non-bonded 
interactions beyond the short range cutoff. 43 Additional potential energy calculation and analysis 
was performed using Molecular Operating Environment. 44 
2.6 Statistical Analysis 
GraphPad Prism (GraphPad Software Inc.) was used to perform statistical analysis 
including linear regression, area under the curve (AUC) analysis, and one-way or two-way 
analysis of variance (ANOVA) as appropriate. Two-way ANOVA was used to analyze clinical 
disease scores and weight loss compared to a PBS negative control; one-way ANOVA was used 
to analyze disease score AUC. Significance threshold was determined by p<0.05 followed by 
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Bonferroni’s multiple comparisons test. Additional statistics and data analysis for molecular 
dynamics energetics were performed using MATLAB. 45  
 
3. Results 
DLS, molecular dynamics, and animal studies were surveyed to probe the role of SAgA 
design elements in co-delivery of both autoantigen and secondary signals. These techniques were 
specifically selected to compliment methods used in our previous publications. 21, 22, 46 Different 
approaches to co-delivery of PLP and LABL were probed (Table 1D-G). A SAgAPLP:LABL 
molecule grafted with both PLP and LABL was included to evaluate the importance of two-
signal presentation on a single HA backbone (Table 1D). A homopolymer mixture containing 
both HAPLP and HALABL in a 1:1 molar ratio (Table 1E) was included to evaluate the importance 
of two-signal presentation on different HA backbones. A SAgA component mixture containing 
free PLP, LABL, and HA in a 10:10:1 molar ratio (Table 1F), which resembled the 
SAgAPLP:LABL molecule in non-conjugated form, was included to evaluate the importance of 
linking all components. A peptide mixture containing PLP and LABL in a 1:1 molar ratio (Table 
1G) was included to evaluate the importance of using HA as a carrier for co-delivery of the two 
peptides. 
3.1 Synthesis and Characterization of Soluble Antigen Arrays 
SAgAs were analyzed by RP-HPLC for approximate molecular weight and peptide 
conjugation as described previously. 21 HPLC results indicated that SAgAPLP:LABL contained 
approximately 9 PLP and 8 LABL peptides per HA backbone, while homopolymers HAPLP and 
HALABL contained 10 or 12 peptides per HA backbone, respectively (Table 1, B-D).  
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3.2 Dynamic Light Scattering Demonstrates Aggregation and Formation of Nanoparticles 
Dynamic light scattering was used to determine particle hydrodynamic radius (Rh, 
Equation 1). Particle size distributions were reported as the number-weighted hydrodynamic 
diameter (Dh) of each sample. HA is naturally polydisperse and consists of a range of molecular 
weights centered around 16 kDa. Therefore, it was expected that resulting particles (e.g. globular 
molecules or molecular complexes) of HA and HA-derived SAgAs would be somewhat 
polydisperse in size.  
HA and SAgAPLP:LABL particle sizes were first evaluated at various sample concentrations 
(0.0134 to 0.428 mM) in order to determine an appropriate concentration for further DLS 
characterization. The concentration range included 0.214 mM, equivalent to the in vivo dose used 
in animal studies (i.e., 2 mM of PLP, or approximately 10X the moles of SAgAPLP:LABL with ~10 
PLP per HA backbone). Linear regression indicated no statistical dependence of Dh on HA or 
SAgAPLP:LABL concentration in this range (Figure 1A). Therefore, a molar concentration of 
0.0625 mM, equivalent to 1 mg/ml HA, was used for remaining DLS studies (Table 1, Figure 
1C). Upon comparison of all groups at this concentration, SAgAPLP:LABL was observed to have 
the largest Dh at 8.85 ± 0.92 nm, followed by the homopolymer mixture (HALABL+HAPLP). The 
peptide mixture (PLP+LABL) was observed to have the smallest Dh at 0.89 ± 0.15 nm, although 
this is approaching the lower limit of detection.  
HA particle size at 0.0625 mM was further investigated as a function of salt 
concentration in 0.1M ammonium acetate buffer to observe aggregation behavior (Figure 1B). 
Particle size was predicted to decrease with increasing NaCl concentration due to the salt 
disrupting ionic or hydrogen bonding sites, thus preventing intermolecular interactions and 
reducing aggregation. By linear regression, Dh was found to significantly decrease with 
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increasing NaCl molarity (p<0.01). The data suggested the particles observed by DLS in PBS 
(0.137 M NaCl) were aggregates of individual polymer molecules. 
Measured particle Dh was compared to the empirical Dh (𝐷!∗) derived for HA, calculated 
from Equation 2 as previously reported (MW in kDa): 47, 48 
  𝐷!∗ = 2 0.87 ∙𝑀𝑊!.!"     (Equation 2) 
Dh values measured by DLS were lower than those calculated by Equation 2. Empirical 𝐷!∗ of 
HA (16 kDa) was 9.98 nm, roughly twice as large as the measured value of 5.32±1.30 nm. 
Similarly, 𝐷!∗ of SAgAPLP:LABL (39 kDa) was 17.50 nm, compared to the measured value of 
8.85±0.93 nm. Equation 2 dictates that HA particle size should increase directly with polymer 
MW. While this trend held true for SAgAPLP:LABL in relation to HA, it did not hold true for 
HAPLP (32 kDa)  and HALABL (28 kDa) which were calculated to have 𝐷!∗ of 15.45 and 14.20 nm, 
respectively. This discrepancy suggests the conjugated peptides may alter the conformation, and 
thus Dh, of the homopolymers and SAgAPLP:LABL. 
3.3 Clinical EAE Studies Indicate Therapeutic Efficacy 
Animal studies were performed in SJL/J mice using experimental autoimmune 
encephalomyelitis (EAE) induced with PLP139-151 to model the relapsing-remitting form of MS. 
Disease symptoms emerged on day 10-12 with peak of disease occurring on day 13-15 before 
progressing to remission around day 20-25. Statistical differences were determined by comparing 
treated groups with the negative PBS control (Table 2). Mice treated with SAgAPLP:LABL had 
better clinical outcomes than mice treated with other groups based on evaluation of clinical score 
(Figure 2), clinical score area under the curve (AUC) relative to PBS controls (Figure 3), and % 
weight change (Supplementary Figure S1).  
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Clinical response to SAgAPLP:LABL treatment was observed across four separate studies 
(Figure 2A-D). SAgAPLP:LABL significantly alleviated EAE disease score compared to the PBS 
control in each Figure 2 study as follows: A) day 12-14 (p<0.01); B) day 11 (p<0.001), day 12-
15 (p<0.0001), and day 17 (p<0.05); C) day 11-14 (p<0.0001) and day 15 (p<0.01); D) day 11 
(p<0.001), day 12-15 (p<0.0001), and day 16 (p<0.01). The homopolymer mixture 
(HAPLP+HALABL) also significantly alleviated disease score on day 11-12 (p<0.001), day 13 
(p<0.01), and day 14-15 (p<0.0001) compared to the PBS control (Figure 2B). Additionally, 
treatments with SAgAPLP:LABL and the homopolymer mixture significantly reduced weight loss 
on day 11-16 (p<0.01) and day 11-15 (p<0.05), respectively (Supplementary Figure S1). In 
contrast, the component mixture (HA+PLP+LABL) only alleviated disease score on day 11 
(p<0.001), while the peptide mixture (PLP+LABL), HAPLP, HALABL, and HA did not 
significantly alleviate disease score or reduce weight loss on any day of the study. (Figure 2, 
Table 2) 
EAE disease score AUC was determined by taking the area under the curve from the 
clinical disease score profiles for each treatment group in Figure 2, relative to the PBS control 
(Figure 3, Table 2). AUC representation of clinical data has been reported as an informative 
secondary measure for overall extent of disease because it provides a cumulative measure that is 
not weighted or biased by the scaling or time course of disease. 49 SAgAPLP:LABL treatment 
exhibited the lowest cumulative disease score relative to the PBS control (p<0.0001). The 
cumulative disease score of the homopolymer mixture treatment group was also significantly 
lower than the PBS control (p<0.01), suggesting these homopolymers may facilitate co-delivery 
of PLP and LABL. In contrast, administration of HAPLP, HALABL, HA alone, the component 
mixture, or the peptide mixture did not significantly reduce extent of disease compared to PBS.  
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3.4 Molecular Dynamics Simulations of Soluble Antigen Arrays 
The potential for co-delivery of SAgA components was assessed using computational 
modeling of different combinations of HA, PLP, LABL and homopolymers (HAPLP and 
HALABL). Molecular dynamics simulations were performed on structures from each group (Table 
1) over 20-40 ns. Analysis of molecular energies over these time periods indicated the molecules 
reached energetic stability after 20 ns. Final molecular conformations were shown as a side angle 
image in addition to a Van der Waals (VDW) surface. The latter viewing angle was from the 
right side at an approximate 45° angle above the long axis.  
3.4.1 Final Conformations of Soluble Antigen Arrays 
The final conformation of the HA backbone resembled a random coil (Table 1A, Figure 
S2), as expected from the literature on HA in solution. 50, 51 The final conformations of single 
SAgAPLP:LABL (Table 1D, Figure 4), HALABL (Table 1B, Figure S3), and HAPLP (Table 1C, Figure 
S4) molecules demonstrated a tendency for PLP and/or LABL side chain interactions both with 
neighboring peptides and with the HA backbone.  
Following a 20 ns simulation, the final SAgAPLP:LABL molecule conformation exhibited 
an approximate chain diameter of ~30 Å and an end-to-end distance of ~300 Å (Figure 4). The 
HA backbone of SAgAPLP:LABL turned and kinked in a helical fashion. Despite the helical nature 
of the individual SAgAPLP:LABL, a simulation of two aligned SAgAPLP:LABL molecules did not 
adopt a helical conformation (Figure 5). The neighboring SAgAPLP:LABL molecules remained 
fairly linear, did not contract into a ball or coil tightly, but did demonstrate a tendency for side 
chain entanglement with the side chains and HA backbone of the neighboring SAgAPLP:LABL 
molecule. Side chain entanglement occurred primarily through heterotypic peptide interactions. 
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Molecular dynamics simulations were then applied to a mixture of homopolymers and a 
mixture of PLP, LABL, and HA. A single HAPLP aligned next to a single HALABL molecule (1:1 
homopolymer mixture) exhibited significant intermolecular interactions between the peptide side 
chains and HA backbone, leading to chain entanglement (Table 1E, Figure 6). In contrast, the 
mixture of free, unlinked PLP, LABL, and HA (SAgA component mixture) exhibited minor 
interactions between the peptides and HA backbone, instead favoring the formation of primarily 
heterotypic peptide:peptide complexes (Table 1F, Figure 7). This result was corroborated by 
simulating a mixture of free PLP and LABL (peptide mixture), which exhibited weak 
intermolecular interactions and random aggregation (Table 1G, Figure 8).  
3.4.2 Energetics of Soluble Antigen Array Simulations 
The potential energy of each system was monitored over the duration of the simulations 
(Figure S5). Change in potential energy (PE) was presented as relative PE % relaxation from the 
initial simulation state, calculated from the final PE (PEf) and initial PE (PEi) as follows (Table 
3): 
𝑃𝐸  %  𝑅𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 =    !"!!!"!
!"!
    Equation 3 
Total PE % relaxation values were rather small (less than 1%) given the large energetic values of 
these systems. PE % relaxation was also calculated for the first half and last half of the 
simulations (Table 3). The latter stages of the simulations exhibited negligible change in PE over 
time, indicating energetic equilibrium and conformational stability were reached (Figure S5). 
Small spikes in energy are typically observed in large molecule simulations, for which 
fluctuations in side chain and backbone conformations cause rapid, momentary changes in 
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energy. The lack of significant changes in average energy over time, however, indicated no 
significant conformation changes occurred during these intervals.  
PE % relaxation was compared among the simulations carried out over 40 ns, which 
included the homopolymer mixture (Figure S5E), SAgA component mixture (Figure S5F), and 
peptide mixture (Figure S5G). The homopolymer mixture exhibited the greatest PE % relaxation 
(0.1316%) compared to the component mixture (0.0931%) and the peptide mixture (0.0740%), 
signifying that greater conformational stability was reached at the end of the homopolymer 
mixture simulation (Table 3). 
 
4. Discussion 
Physicochemical properties of antigen arrays are known to skew the immune response 
towards immunogenicity or tolerance. 10 Several investigators have proposed a correlation 
between immune response and antigen array properties such as polymer size, flexibility, antigen 
valency, and antigen spacing, suggesting these properties affect the ability of an array to cluster 
cell surface receptors and elicit a given immune response. 8, 12, 14-16, 19, 52, 53 Moreover, multivalent 
antigen arrays provide an effective platform for the co-delivery of primary autoantigen and 
secondary signal in spatial and temporal proximity. Inclusion of a secondary costimulatory or 
inhibitory signal may shift the immune response to a given antigen towards protection or 
tolerance, respectively. 11, 18, 33, 54-58 Such an array facilitates two-signal co-delivery by localizing 
exposure of the immune system to antigen and secondary signal within the same time and space. 
Delivery of both signals in this context may be important for eliciting the desired immune 
response due to (1) co-delivery to the tissue of interest and (2) engaging and clustering cell 
surface receptors to initiate a cellular response. 10 
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Clinical EAE studies revealed that inclusion of both antigen and secondary signal were 
required for therapeutic efficacy, as the groups lacking two signals (HA, HAPLP, and HALABL) 
did not alleviate disease. In addition, neither group containing a physical mixture of the two 
signals (component mixture and peptide mixture) alleviated disease, indicating that mere 
presence of both signals did not render efficacy. Rather, the groups containing both signals in 
linked arrays (SAgAPLP:LABL and homopolymer mixture) significantly alleviated disease, 
indicating that co-delivery of both signals was necessary for efficacy. Others have also shown 
that conjugation between all components of an antigen-specific immunotherapy was necessary to 
achieve desired immune modulation. 34, 58-62 Previously, we showed there was no difference in 
cytokine profiles generated from EAE mice splenocytes following ex vivo treatment with a 
mixture of HA, PLP, and LABL versus conjugated SAgAPLP:LABL. The ex vivo cytokine 
screening environment effectively contains both signals in the same time and space (i.e., all 
components are together within the same well). 22 These results suggest an in vivo delivery 
mechanism in which HA acts as a carrier for the co-delivery of autoantigen and secondary signal 
to the site of interest.  
Transport to the site of interest, such as secondary lymphoid organs, is an important 
determinant for therapeutic efficacy. A major factor determining transport following 
subcutaneous injection is hydrodynamic diameter. Depending on the site of administration, 
particles <10 nm tend to drain into systemic circulation, particles between 10-70 nm tend to drain 
into the lymphatics, and particles >70 nm tend to form a depot at the injection site. 10, 47, 63-69 DLS 
size distributions of SAgAPLP:LABL and the homopolymer mixture overlapped with the 10 nm 
threshold, suggesting these could drain with interstitial fluid through the peripheral lymphatics to 
allow for encounters with resident APCs. While the average particle sizes of SAgAPLP:LABL 
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(8.85±0.92 nm) and homopolymer mixture (6.69±1.19 nm) at simulated physiological conditions 
were the largest among all groups, they did not differ significantly from the particle sizes of HA, 
HAPLP, HALABL, or the SAgA component mixture. In contrast, the particle size of the peptide 
mixture (0.89±0.15 nm) was significantly smaller. The particle size distribution was sufficiently 
below the 10 nm threshold such that peptide drainage into systemic circulation was highly 
probable, increasing clearance and reducing efficacy. 66  
Building upon this hypothesized mechanism of transport, molecular dynamics 
simulations allowed us to predict likely molecular conformations to better understand why 
certain groups (i.e. homopolymer mixture) might facilitate two-signal co-delivery to improve 
treatment efficacy, while others (i.e. component mixture, peptide mixture) do not. The significant 
intermolecular interactions and peptide/polymer chain entanglement exhibited by neighboring 
molecules in the homopolymer mixture suggest effective co-delivery of both signals as if 
presented along a single backbone. Conversely, the weak, random interactions exhibited by 
molecules in the peptide mixture and SAgA component mixture (i.e. HA, PLP, and LABL) may 
not provide a sufficiently stable vehicle for spatial and temporal co-delivery of both signals.  
Furthermore, comparison of PE % relaxation between the homopolymer mixture, 
component mixture, and free peptide mixture over a 40 ns simulation revealed the greatest % 
relaxation for the homopolymer mixture. The greater reduction in PE exhibited by the 
homopolymer mixture signified that greater conformational stability was achieved through 
intermolecular interactions between the homopolymers, compared to intermolecular interactions 
between the components (HA, PLP, LABL) or free peptides (PLP, LABL). Thus, intermolecular 
complexes formed in the homopolymer mixture may be more likely to persist after 
administration in vivo, potentially facilitating co-delivery. If the weaker complexes formed by 
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the component mixture do not persist under physiological conditions, it increases the probability 




Two-signal co-delivery is an important factor for directing immune response. Our results 
from previous publications suggest it is critical for alleviating disease in EAE. 21, 22 Multivalent 
soluble antigen arrays offer promising options for antigen-specific immunotherapy and provide a 
platform for two-signal co-delivery. SAgAPLP:LABL and a mixture of HAPLP+HALABL were found 
to be therapeutically effective in EAE through co-delivery of primary autoantigen, PLP, and a 
secondary inhibitory signal, LABL. DLS and molecular dynamics simulations shed light on the 
mechanisms by which co-delivery was achieved. It is believed that therapeutically effective 
antigen arrays possessed physical characteristics that facilitated co-transport of the two signals. 
Intermolecular interactions and chain entanglement suggested facilitation of two-signal co-
delivery via entangled homopolymers each displaying one signal. These findings refine our 
understanding of the mechanisms by which soluble antigen arrays enact their therapeutic effect, 
and guide the development of future multivalent antigen-specific immunotherapies.  
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Table 1. Visual diagrams and characteristics of each sample used for dynamic light scattering 
(DLS) characterization and animal studies.  
Sample 
Molar Ratio per  





Dh in PBS 
(nm)d 
A) HA 0:0:1 16 5.32 ± 1.30 
B) HALABL 0:12:1 28 5.94 ± 0.84 
C) HAPLP 10:0:1 32 3.52 ± 0.44 




10:12:2 n/a 6.69 ± 1.19 
F) SAgA component 
mixture:  
HA+PLP+LABL  
10:10:1 n/a 4.48 ± 0.89 
G) Peptide mixture:  
 PLP+LABL 
1:1:0 n/a 0.89 ± 0.15 
aPeptide molar conjugation was determined by reverse-phase HPLC and results are an average of 
triplicate injections from a single batch preparation.  
bHA, hyaluronic acid; PLP, proteolipid protein peptide; LABL, inhibitor peptide derived from 
leukocyte function associated antigen-1 
cCalculated from RP-HPLC data. MW, molecular weight. 
dDetermined by DLS at a concentration of 0.0625 mM in PBS (n=5). Dh, hydrodynamic 
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Days of Significance a 
% Weight Change  
Days of Significance a 
Disease Score AUC 
Relative to PBS b 
Two-Component Co-delivery Systems 
SAgAPLP:LABL  
Day 11 (p<0.001) 
Day 12-15 (p<0.0001) 
Day 16 (p<0.01) c 
Day 11-14 (p<0.0001) 
Day 15 (p<0.001) 
Day 16 (p<0.01) c 
0.38 ± 0.22 
(p<0.0001) d 
HAPLP+HALABL 
Day 11-12 (p<0.001) 
Day 13 (p<0.01)  
Day 14-15 (p<0.0001) 
Day 11, 13 (p<0.01) 
Day 12, 14-15 (p<0.05) 
0.44 ± 0.41 
(p<0.01) 
Two-Component Mixtures 
HA+PLP+LABL e Day 11 (p<0.001) ns 0.72 ± 0.35 
PLP+LABL ns ns 1.05 ± 0.26 
Single-Component Controls 
HAPLP ns ns 0.68 ± 0.43 
HALABL ns ns 1.11 ± 0.63 
HA  ns ns 0.95 ± 0.39 
PBS ns ns 1.00 ± 0.46 d 
aStatistical significance determined relative to PBS using two-way ANOVA followed by 
Bonferroni’s post-hoc test with p<0.05 (n=6 per treatment group) 
bData expressed as mean ± SD (n=6 unless otherwise noted). AUC relative to PBS, where PBS = 
1. AUC, area under the curve; PBS, phosphate-buffered saline. 
cData from study in Figure 2D. 
dAverage of four pooled studies from Figure 2 (n=24) 
eHA, hyaluronic acid; PLP, proteolipid protein peptide; LABL, inhibitor peptide derived from 
leukocyte function associated antigen-1; ns, no statistical significance. 
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Table 3. Relative potential energy (PE) % relaxation over the duration of the simulations 





PE % Relaxationa 
Total First Half 
Last 
Half 
Homopolymer Mixture (HAPLP+HALABL) 40 0.1316 0.1117 0.0198 
Component Mixture (HA+PLP+LABL) 40 0.0931 0.0781 0.0150 
Free Peptide Mixture (PLP+LABL) 40 0.0740 0.0638 0.0101 
SAgAPLP:LABL x2 10 0.0607 0.0541 0.0066 
HA 10 0.0467 0.0393 0.0074 
HAPLP 10 0.0408 0.0234 0.0174 
SAgAPLP:LABL 20 0.0314 0.0311 0.0003 
HALABL 20 0.0302 0.0253 0.0049 
a % Relaxation values were calculated from Equation 3. PE absolute values were determined 
from Desmond molecular dynamics simulations. PE, potential energy. 
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Figure 1. Nanoparticle characterization: Number-weighted hydrodynamic diameter (Dh) 
determined by dynamic light scattering (DLS). A) Particle size dependence of HA and 
SAgAPLP:LABL on solute molarity. Linear regression indicated no statistical dependence of HA or 
SAgAPLP:LABL particle size on solute concentration in this range.  B) Particle size distribution of 
all groups at 0.0625 mM in PBS. C) Particle size dependence of HA on solvent NaCl molarity. 
Linear regression determined HA particle size was statistically dependent (p<0.01) on NaCl 
concentration in this range. Data presented as mean±SD (n=5) with p<0.05.  
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Figure 2. Clinical EAE disease scores in mice comparing treatment groups to a PBS negative 
control across four separate studies: A) SAgAPLP:LABL, HALABL, and HAPLP; B) SAgAPLP:LABL and 
homopolymer mixture (HAPLP+HALABL); C) SAgAPLP:LABL, component mixture 
(HA+PLP+LABL), and HA alone; and D) SAgAPLP:LABL and peptide mixture (PLP+LABL). 
SAgAPLP:LABL significantly alleviated EAE disease score compared to the PBS control in each 
study as follows: A) day 12-14 (p<0.01); B) day 11 (p<0.001), day 12-15 (p<0.0001), and day 
17 (p<0.05); C) day 11-14 (p<0.0001) and day 15 (p<0.01); D) day 11 (p<0.001), day 12-15 
(p<0.0001), and day 16 (p<0.01). The homopolymer mixture (HAPLP+HALABL) significantly 
alleviated disease score on day 11-12 (p<0.001), day 13 (p<0.01), and day 14-15 (p<0.0001) 
compared to the PBS control (B). The component mixture (HA+PLP+LABL) significantly 
alleviated disease score on day 11 (p<0.001) (C). Data presented from four separate studies as 
mean+SD using a two-way ANOVA followed by Bonferroni’s multiple comparisons test with 
p<0.05 (n=6).  
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Figure 3. Relative EAE disease score area under the curve: Area under the curve (AUC) of 
clinical EAE disease scores in mice relative to the PBS control, indicating therapeutic efficacy. 
Relative disease score AUC shows SAgAPLP:LABL (****p<0.0001) and homopolymer mixture 
(**p<0.01) significantly alleviated disease compared to PBS. Data presented as mean+SD. 
Statistical significance determined using one-way ANOVA in comparison to PBS followed by 
Bonferroni’s multiple comparison test with p<0.05 and n=6 (for PBS and SAgAPLP:LABL, n=24).   
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Figure 4. SAgAPLP:LABL molecular dynamics: Single SAgAPLP:LABL molecule in A) initial 
conformation prior to molecular dynamics simulation, B) final conformation after a 40 ns 
molecular dynamics simulation in side view, and C) final conformation in angled view of VDW 
surface. Helical behavior was exhibited by the molecule. Dimensions in Å.   
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Figure 5. Neighboring SAgAPLP:LABL molecular dynamics: Two SAgAPLP:LABL molecules (green 
and cyan) shown in A) initial conformation prior to molecular dynamics simulation, B) final 
conformation after a 20 ns molecular dynamics simulation in side view, and C) final 
conformation in angled view of VDW surface. Intermolecular side chain interactions were 
exhibited between the neighboring molecules. Dimensions in Å. 
	  
	   73	  
 
Figure 6. Homopolymer mixture (HAPLP+HALABL) molecular dynamics: One HAPLP (cyan) plus 
one HALABL (green) molecule shown in A) initial conformation prior to molecular dynamics 
simulation spaced approximately 20 Å apart, B) final conformation after a 40 ns molecular 
dynamics simulation in side view, and C) final conformation in angled view of VDW surface. 
Significant intermolecular interactions between peptide side chains and HA backbone were 
exhibited between the neighboring molecules, leading to chain entanglement. Dimensions in Å.  
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Figure 7. Component mixture (HA+PLP+LABL) molecular dynamics: Free, unlinked PLP 
(cyan), LABL (green), and HA (10:10:1) shown in A) initial conformation prior to molecular 
dynamics simulation, B) final conformation after a 40 ns molecular dynamics simulation in side 
view, and C) final conformation in angled view of VDW surface. Minor interactions between the 
peptides and HA backbone were exhibited, instead favoring the formation of primarily 
heterotypic peptide:peptide complexes. Dimensions in Å.  
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Figure 8. Peptide mixture (PLP+LABL) molecular dynamics: Free, unlinked LABL (green) and 
PLP (cyan) peptides (1:1) shown in A) initial conformation in a cube arrangement with ~70 Å in 
each dimension prior to molecular dynamics simulation, B) final conformation after a 40 ns 
molecular dynamics simulation in side view, and C) final conformation in front view. Weak 
intermolecular interactions and random aggregation were exhibited between peptides. 
Dimensions in Å. 
	  




Supplemental Figure 1. Percent weight change in EAE clinical studies, comparing PBS 
negative control to A) SAgAPLP:LABL and individual homopolymers HAPLP and HALABL, B) 
SAgAPLP:LABL and homopolymer mixture (HAPLP + HALABL) C) SAgAPLP:LABL, component 
mixture (HA + PLP + LABL), and HA alone, and D) SAgAPLP:LABL and peptide mixture (PLP + 
LABL). SAgAPLP:LABL significantly reduced weight loss compared to the PBS control in each 
study as follows: A) day 12 (p<0.05) and day 14 (p<0.01); B) day 11 and 13 (p<0.001), day 12 
(p<0.01), day 14-16 (p<0.0001), and day 17 (p<0.05); C) day 10 (p<0.05) and day 11-20 
(p<0.0001); D) day 11-14 (p<0.0001), day 15 (p<0.001), and day 16 (p<0.01). The 
homopolymer mixture (HAPLP+HALABL) also significantly reduced weight loss on day 11 and 13 
(p<0.01) and day 12, 14-15 (p<0.05) (B). Data presented from four separate studies as mean+SD 
using a two-way ANOVA followed by Bonferroni’s multiple comparisons test with p<0.05 
(n=6).  
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Supplemental Figure 2. Final conformation of 16 kDa HA following a 20 ns molecular 
dynamics simulation, showing A) side view and B) angled view of VDW surface. The final 
conformation resembled a random coil. Dimensions in Å. 
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Supplemental Figure 3. Final conformation of HALABL following a 20 ns molecular dynamics 
simulation, showing A) side view and B) angled view of VDW surface. A tendency for LABL 
side chain interactions with neighboring peptides and the HA backbone was exhibited. 
Dimensions in Å. 
  
	  



















Supplemental Figure 4. Final conformation of HAPLP following a 20 ns molecular dynamics 
simulation, showing A) side view and B) angled view of VDW surface. A tendency for PLP side 
chain interactions with neighboring peptides and the HA backbone was exhibited. Dimensions in 
Å.
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Supplemental Figure 5. Molecular dynamics potential energy (kcal/mol) versus time (ns) over 
the duration of the simulation: A) HA, B) HALABL, C) HAPLP, D) SAgAPLP:LABL, E) 
homopolymer mixture (HAPLP + HALABL), F) component mixture (HA + PLP + LABL), G) 
peptide mixture (PLP + LABL), H) SAgAPLP:LABL x2. Negligible changes in PE over the latter 
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Supplemental References for Molecular Dynamics Methods 
The molecular dynamics simulations were performed using Desmond software. 
S1. Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, J. L.; Klepeis, 
I. K.; Moraes, M. A.; Sacerdoti, F. D.; Salmon, J. K.; Shan, Y.; Shaw, D. E., Scalable 
Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of 
the ACM/IEEE Conference on Supercomputing (SC06) 2006. 
The force field used for simulations was OPLS2005 as available in Desmond. 
S2. Kaminski, G. A.; Friesner, R. A., Evaluation and reparameterization of the OPLS-AA 
force field for proteins via comparison with accurate quantum chemical calculations on 
peptides. J Phys Chem B 2001, 105 (28), 6474-6487. 
The Nose-Hoover thermostat was used to control temperature.  
S3. Hoover, W. G., Canonical dynamics: equilibrium phase-space distributions. Phys Rev A 
1985, 31, 1695-1697. 
The Martyna-Tobias-Klein barostat was used to control pressure. 
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S4. Martyna, G. J.; Tobias, D. J.; Klein, M. L., Constant pressure molecular dynamics 
algorithms. J Chem Phys 1994, 101, 4177-4189. 
Coulombic interactions were calculated using the Ewald smooth particle-mesh approach. 
S5. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G., A 
smooth particle mesh Ewald method. J Chem Phys 1995, 103, 8577-8593. 
The RESPA integrator was used with 2 fs time step intervals for bonded/non-bonded interactions 
at short ranges, and a 6 fs step was used for non-bonded interactions beyond the short range 
cutoff. 
S6. Humphreys, D. D.; Friesner, R. A.; Berne, B. J., A multiple-time-step molecular 
dynamics algorithm for macromolecules. J Phys Chem 1994, 98, 6885-6892. 
Additional potential energy calculation and analysis was performed using Molecular Operating 
Environment. 
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Chapter III: Antigen-Specific Binding of Multivalent 
Soluble Antigen Arrays Induces Receptor Clustering and 
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1. Introduction 
Autoimmunity stems from the immune system’s misrecognition of self versus non-self 
epitopes, leading to an autoreactive T and/or B cell response against autoantigens. 1, 2 Due to 
their multifaceted role in autoimmunity, B cells are a likely target for autoimmune therapies. 
Various treatment approaches (i.e. glucocorticoids, IFNβ, mitoxantrone, rituximab) affect B 
cells, but do so in a non-specific manner resulting in general B cell depletion or down-regulation. 
3, 4 In fact, many current therapies for autoimmune diseases act broadly against the immune 
response, lacking the capability to target specific immune cells and pathways responsible for 
disease propagation. 5 These options often yield limited therapeutic efficacy, global 
immunosuppression, and adverse side effects for patients. 6-8 A pressing need persists for 
antigen-specific immunotherapies (ASITs) that shift the autoreactive immune response towards 
selective autoantigenic tolerance while avoiding deleterious global immunosuppression. 9-11  
T cells and B cells, which are responsible for antigen specificity, memory, diversity, and 
self-recognition in acquired immunity, are often dysfunctional in autoimmunity. The 
autoimmune breakdown in MS is believed to be triggered by both autoreactive T cell and B cell 
clonal expansion and attack against myelin sheath autoantigens, leading to chronic inflammation, 
demyelination, and subsequent axonal and neuronal degeneration. 6, 7, 12-14 T cell-mediated attack 
against autoantigens following T cell clonal expansion is propagated by the immunological 
synapse between antigen presenting cells (APC) and T cells. 15-17 This signaling event requires 
both a primary antigen-specific signal and a secondary context signal, which may be 
costimulatory or inhibitory to direct the immune response towards the antigen. 18-24 B cells may 
play a role in the priming and activation of naïve T cells by acting as antigen presenting cells, 
and may also contribute to autoimmunity by several humoral immune response pathways. 25-27 
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Elevated levels of clonally expanded B cells, myelin-specific plasma cells, and memory B cells 
in cerebrospinal fluid (CSF) and of myelin-specific autoantibodies in CSF, serum, and MS 
lesions have implicated B cells in the pathogenesis and immune regulation of multiple sclerosis. 
11, 26, 28-35 Like other autoimmune diseases, MS is plagued by a lack of safe and effective 
treatments that offer antigen specificity without broad immune suppression. 
To address this need, we have developed soluble antigen arrays (SAgAs), which are 
polymeric multivalent ASIT molecules designed to induce selective antigenic tolerance in MS. 36 
SAgAPLP:LABL molecules consist of a hyaluronic acid (HA) linear polymer backbone co-
presenting both myelin autoantigen peptide (proteolipid protein peptide, PLP139-151) and 
intracellular adhesion molecule-1 (ICAM-1) inhibitor peptide derived from leukocyte function 
associated antigen-1 (LFA-1), LABL. Preclinical studies in experimental autoimmune 
encephalomyelitis (EAE), a murine model of MS, showed that treatment with SAgAPLP:LABL was 
effective at alleviating disease. In contrast, treatment with a mixture of the components (HA, 
PLP, LABL), HA alone, HA grafted with PLP only (HAPLP), or HA grafted with LABL only 
(HALABL) did not alleviate disease, indicating that co-presentation of both signals on HA was 
necessary for therapeutic efficacy. 37 SAgAPLP:LABL molecules are hypothesized to target, engage, 
and interrupt antigen-specific signaling by presenting both primary autoantigen and secondary 
inhibitory signals, thereby inhibiting autoreactive T cell and/or B cell clonal expansion while 
promoting selective autoantigenic tolerance. 38, 39 A main mechanism for SAgAPLP:LABL 
therapeutic efficacy, therefore, may be the enhanced ability of the molecule to bind APCs 
involved in the immunological synapse or other PLP-specific signaling pathways. We 
hypothesize that incorporation of both signals in a multivalent array causes (1) an increase in 
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overall binding with APCs, (2) specific binding due to targeting by the antigenic peptide, and (3) 
modulation of the cell signaling response. 
The binding properties of SAgAPLP:LABL (two-signal multivalent array) were compared to 
‘homopolymers’ containing one signal (HAPLP or HALABL), and to the polymer backbone alone 
(HA). Due to their antigen specificity and implication in immune regulation, B cells were chosen 
as a model cell system in which to observe SAgA binding. The B cell receptor (BCR) imbues B 
cells with a superior ability to specifically bind and concentrate antigen over other types of cells, 
making them highly efficient APCs. 3, 40, 41 Flow cytometry was performed with immortalized 
human Raji B cells and fluorescently labeled SAgA molecules (fSAgAs) to quantify binding 
extent and specificity. Fluorescence microscopy supplemented these studies with visualization of 
real-time fSAgA binding and progressive receptor clustering in live cells. Calcium flux flow 
cytometry assays were used to probe the signaling response. These studies revealed molecular 
mechanisms that may contribute to SAgAPLP:LABL therapeutic efficacy, and more broadly, 
strengthen our understanding of antigen-specific multivalent immunotherapies designed for the 
effective treatment of autoimmune disease. 
 
2. Materials and Methods 
2.1 Materials 
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN). Aminooxy-LABL (AoLABL, Aoa-itDGEATDSG-OH), aminooxy-
PLP (AoPLP, Aoa-HSLGKWLGHPDKF-OH), LABL (NH2-itDGEATDSG-OH), and PLP 
(NH2-HSLGKWLGHPDKF-OH) peptides were purchased from PolyPeptide Laboratories (San 
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Diego, CA). Fluorescein isothiocyanate (FITC) and Fluo-4 AM calcium indicator were 
purchased from Thermo Fisher Scientific (Waltham, MA). Immortalized human Raji B cells 
were purchased from American Type Culture Collection (ATCC, Manassas, VA). Recombinant 
human tumor necrosis factor-α (TNF-α) was purchased from PeproTech (Rocky Hill, NJ). R-
phycoerythrin (PE)-conjugated anti-human CD54, FITC-conjugated anti-human CD44, purified 
anti-human IgM, and respective isotype control antibodies were purchased from BioLegend (San 
Diego, CA). Affinity purified F(ab’)2 fragment goat anti-human IgM was purchased from 
Jackson ImmunoResearch Laboratories (West Grove, PA). All other chemicals and reagents 
were analytical grade and used as received. 
2.2 Peptide Synthesis 
OVA peptide (NH2-ISQAVHAAHAEINEAGR-OH) was synthesized as previously 
described, 42 using 9-fluorenylmethylmethyloxycarbonyl-protected amino acid chemistry on 
polyethylene glycol-polystyrene resins. Peptides were deprotected, cleaved from resin, and 
isolated using precipitation in ether, then purified by preparatory high performance liquid 
chromatography (HPLC) followed by lyophilization. Peptide identity was confirmed by 
electrospray ionization mass spectroscopy. Purity was evaluated by analytical HPLC.  
2.3 SAgA and FITC-Labeled SAgA Synthesis 
To synthesize SAgAs, HA was grafted with aminooxy peptides AoPLP and/or AoLABL 
as previously described to make HAPLP (HA and AoPLP), HALABL (HA and AoLABL), and 
SAgAPLP:LABL (HA, AoPLP, and AoLABL). 36 HA was dissolved (2 mg/ml) in a 20mM acetate 
buffer at pH 5.5, then combined with respective peptide(s) to achieve a target conjugation 
efficiency per peptide of 25% (or approximately 10 of each peptide per fHA backbone). Solution 
pH was readjusted to pH 5.5 and stirred at 400 rpm for 24 hours. Samples were dialyzed in d.d. 
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H2O (100X volume) to remove free peptides using 6000-8000 MWCO regenerated cellulose 
dialysis tubing over 24 hours with a total of 4 washes, then frozen and lyophilized. 
To synthesize FITC-labeled SAgAs (fSAgAs), HA (16 kDa) was first reacted with FITC 
to make labeled HA-FITC (fHA). 43 HA was gently dissolved in d.d. H2O (5 mg/ml), then 
combined with an equal volume of DMSO containing sodium bicarbonate (2.5 mg/ml), 
dibutyltin dilaurate (3.96 mM), and FITC (6 mg/ml). The reaction mixture was heated in an oil 
bath at 50°C for 30 minutes while stirring at 70 rpm, then quenched by drop-wise addition to 
cold ethanol (17.5X volume). Dialysis took place in d.d. H2O (100X volume) to remove free 
FITC using 3500 MWCO regenerated cellulose dialysis tubing (Spectrum Laboratories, Rancho 
Dominguez, CA), rinsing every 6-12 hours for a total of six washes. The fHA solution was then 
frozen and lyophilized. Peptide conjugation with fHA was performed as detailed above to make 
fHAPLP, fHALABL, and fSAgAPLP:LABL. All fHA synthesis and subsequent handling was 
performed under protection from light. 
2.4 SAgA and FITC-Labeled SAgA Characterization 
Peptide conjugation of each sample was determined through gradient reverse-phase 
analytical high-performance liquid chromatography (RP-HPLC) (Waters Corp., Milford, MA) on 
a C18 analytical column (Higgins Analytical, Proto200, 5 µm, 200 Å, 250 x 4.6 mm2, Mountain 
View, CA) following cleavage of peptides in 0.1N HCl. Samples were compared to standard 
curves of AoPLP and AoLABL to determine peptide content. A gradient method using aqueous 
mobile phase A (94.9% d.d. H2O, 5% acetonitrile, 0.1% trifluoroacetic acid (TFA)) and organic 
mobile phase B (99.9% acetonitrile, 0.1% TFA) was used to analyze samples. Samples were 
detected at 220 nm. 
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FITC fluorescence intensity varied slightly between fSAgA groups, presenting the need 
to normalize flow cytometry binding results according to respective fluorescence intensities of 
the fSAgA molecules. Relative FITC fluorescence of labeled samples was determined 
spectrofluorometrically on a fluorescent plate reader (SpectraMax M5e, Molecular Devices, 
Sunnyvale, CA). A fluorescence calibration curve was generated for each sample ranging from 0 
to 0.5 mg/ml, and the relative fluorescence intensity (f) was determined in the linear region of the 
calibration curve at 0.4 µM relative to fHA (fHA=1). The relative fluorescence intensity of each 
test article was used to normalize flow cytometry FITC fluorescence.  
2.5 Cell Culture and Activation 
Raji B cells (human B lymphocytes, ATCC) were cultured in RPMI-1640 supplemented 
with L-Glutamine, 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin (P/S) at 37°C 
and 5% CO2. Cell assays were consistently performed after cells reached confluency (~2 weeks) 
and following no more than 8-10 passages, per ATCC guidelines. Cells were activated with 1000 
U/ml TNF-α and primed with 27.1 µM PLP139-151 peptide for 24 hours prior to experiments. Cell 
activation by TNF-α and PLP was examined by flow cytometry for expression of intracellular 
adhesion molecule-1 (ICAM-1, CD54) and CD44. ICAM-1 expression was evaluated using 
mouse anti-human PE-conjugated CD54 and mouse IgG1κ isotype control antibodies. CD44 
expression was evaluated using mouse anti-human FITC-conjugated CD44 and mouse IgG1κ 
isotype control antibodies. 
2.6 Flow Cytometry Binding Studies 
Association and competitive dissociation binding studies were performed by flow 
cytometry (MoFlo XDP Cell Sorter, Beckman Coulter Inc., Brea, CA). Cell nuclei were stained 
with Hoechst, while Q-Nuclear Red or propidium iodide (PI) was used as a dead cell indicator. 
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Cell samples were warmed to 37°C prior to flow cytometry analysis. Data acquisition was 
triggered off the Hoechst signal. Fluorescence was excited using 488, 405, and 640 nm lasers and 
was collected using 529/28, 457/40, and 670/30 bandpass emission filters.  
2.6.1 Maximum Steady State Binding 
To observe maximum steady state binding, cells were mixed with fSAgA to achieve a 
final concentration of 1x106 cells/ml immediately before injecting on the flow cytometer. Sample 
concentration was determined from preliminary saturation studies with fHA. Samples were 
added at an equimolar PLP dose (353.18 µM PLP for fHAPLP and fSAgAPLP:LABL, or 353.18 µM 
LABL for fHALABL) and fHA was dosed at 39.19 µM (the HA molar equivalent to a 353.18 µM 
PLP dose of fSAgAPLP:LABL) to mimic animal studies. The sample was allowed to run until 
maximum steady state binding was reached, at which point ~10X molar excess unlabeled reagent 
(HA, PLP, or LABL) was added to competitively dissociate the bound, labeled SAgA. Samples 
were allowed to run until the dissociation steady state (representing nonspecific binding) was 
reached. fHA, fHALABL, and fHAPLP were dissociated by competition with HA, LABL, and PLP, 
respectively, to determine specificity of binding.  
2.6.2 Competitive Dissociation 
fSAgAPLP:LABL was dissociated by competition with its various unlabeled components 
(HA, PLP, and LABL), including a nonspecific control peptide (OVA), to determine the specific 
binding contribution of each individual component. Dissociation by addition of an equal volume 
of media was included as a control to account for dissociation due to dilution and resulting shift 
in equilibrium. Cells (1x106 cells/ml) were mixed with fSAgAPLP:LABL (444 µM PLP, near-
saturation concentration) and allowed to reach maximum steady state binding, at which point 
~20X molar excess (400 µl) unlabeled HA, PLP, LABL, OVA, or media was added. 
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fSAgAPLP:LABL concentration was determined from preliminary saturation studies with 
fSAgAPLP:LABL. Samples were run until dissociation steady state was reached. 
2.6.3 IgM Blocking 
Raji B cells (106 cells) were incubated with or without mouse anti-human IgM (0.5 µg 
per 100 µl) (BioLegend) for one hour on ice following FcR blocking. Maximum steady state 
binding was performed by flow cytometry as detailed above, to evaluate fSAgAPLP:LABL binding 
following BCR blocking with anti-IgM. fSAgAPLP:LABL was dosed at 353.18 µM PLP with a final 
cell concentration of 1 x106 cells/ml. 
Flow cytometry binding data was first gated to remove dead cells and debris using 
Kaluza Flow Analysis software (Beckman Coulter, Inc., Brea, CA) (Supplemental Figure 1). 
Additional data processing was performed using KNIME software (Konstanz Information Miner, 
KNIME, Zurich, Switzerland). Nonlinear regression and additional statistical analysis was 
performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).  
2.7 Fluorescence Microscopy Using a Microfluidics Platform 
Live cell imaging of fSAgA binding was observed under fluorescence microscopy 
(Olympus IX81 Inverted Epifluorescence Microscope) using the same concentrations from flow 
cytometry association binding experiments. CellASIC ONIX M04S Microfluidics Switching 
Plates and Microfluidics Platform (EMD Millipore, Billerica, MA) were utilized for controlled 
perfusion of fluorescent samples and media with cells during real-time imaging. Raji B cells 
were stained with Hoechst and loaded into the imaging chamber. fSAgA was perfused into the 
chamber for 10 minutes (1 psi for 5 minutes, 0.25 psi for 5 minutes) to allow binding with cells, 
followed by gentle media perfusion (0.25 psi for 5 minutes) to rinse unbound fSAgA, followed 
	  
	   97	  
by immediate image capture (t=0). Images were captured across time intervals of [0-5), [5-10), 
and >10 minutes. Images were analyzed using Slidebook 5.5 (Intelligent Imaging Innovations, 
Inc., Denver, CO). For each sample and time interval, several fields were randomly selected and 
40–200 FITC positive cells total were counted and scored for diffuse versus punctate staining. Of 
the punctate positive cells, ‘fully punctate’ cells were also distinguished. Punctate staining was 
defined by multiple areas of discrete high intensity fluorescence totaling <50% of the cell 
surface; fully punctate staining was defined by one predominant area of discrete high intensity 
fluorescence totaling <50% of the cell surface. The results are a composite analysis of two 
independent experiments. 
2.8 Calcium Flux Signaling Flow Cytometry Assay 
 Raji B cells were loaded with 5 µM Fluo-4 AM for 30 minutes at room temperature in 
PBS, then kept on ice in HBSS (Hanks Balanced Salt Solution) containing 1.3 mM Ca2+ and 0.9 
mM Mg2+ before analysis. Cells were run through a BD FACSFusion cytometer and 
fluorescence was monitored in the 530/30 channel. After baseline quantification for ~1 minute, 
crosslinking goat anti-human IgM (Jackson ImmunoResearch) was added at 20 µg/ml to 
stimulate the cells. Changes in Fluo-4 fluorescence were measured for ~1 minute to establish an 
anti-IgM stimulated baseline, followed by SAgA addition (dosed at 353.18 µM PLP, the same 
concentration used in binding studies) to determine the effect on IgM-stimulated signaling. Data 
was acquired for an additional 3 minutes until steady state was established. To measure 
inhibition of anti-IgM stimulation, SAgAPLP:LABL was added to cells prior to anti-IgM 
stimulation. Data was analyzed using FlowJo, FCS Express, and GraphPad Prism. Baselines 
were subtracted from mean fluorescence intensity levels for each experimental condition.  
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2.9 Resazurin Cell Metabolism Assay 
Cells were plated in a 96-well plate to achieve a final concentration of 1x106 cells/ml in a 
final volume of 150 µl/well. Test compounds (SAgAPLP:LABL, HAPLP, HALABL, and HA) were 
added at a dose of 353.18 µM PLP and incubated for 24 hours at 37°C. Resazurin (0.01% v/v in 
RPMI) was then added to each well (20 µl per 100 µl cells) and incubated for an additional 6 
hours. Resazurin fluorescence (560/590 nm) was measured on a SpectraMax Fluorescent Plate 
Reader.  
2.10 Statistical Analysis 
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test 
(n=3). ANOVA was followed by Tukey’s post-hoc test. The threshold for statistical significance 
was set to p<0.05. 
 
3. Results  
3.1 SAgA and FITC-Labeled SAgA Characterization 
SAgAs and fSAgAs were synthesized and analyzed by RP-HPLC to determine molecular 
weight and peptide conjugation as described previously. 36 HPLC results indicated fHAPLP 
homopolymer contained ~9 PLP, fHALABL homopolymer contained ~10 LABL, and 
fSAgAPLP:LABL contained ~10 PLP and ~13 LABL peptides per HA backbone, respectively 
(Table 1). HAPLP homopolymer contained ~6 PLP, HALABL homopolymer contained ~6 LABL, 
and SAgAPLP:LABL contained ~8 PLP and ~7 LABL peptides per HA backbone, respectively. 
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3.2 Cell Activation 
Raji B cells were evaluated by flow cytometry for CD54 and CD44 expression levels 
following 24-hour activation and priming with TNF-α and PLP. Intercellular adhesion molecule-
1 (ICAM-1, CD54) is expressed on activated immune cells and plays a role in cellular adhesion 
and inflammation; it binds LFA-1 and its cell surface expression is upregulated by cell 
activation. 18, 44, 45 CD44, an adhesion molecule expressed on leukocytes, is also upregulated in B 
and T cells upon activation and progression to the memory cell stage. 46-48  
Comparison of each antibody with isotype and unstained controls showed that neither 
antibody exhibited nonspecific staining (Supplemental Figure 2). Naïve and activated cells 
stained with FITC anti-CD44 exhibited minimal CD44 expression (Figure 1A). Less than 5% of 
the cells were CD44-positive after 24 hours of activation, and expression did not differ 
significantly between unstained, naïve, and activated cells. In contrast, naïve and activated cells 
stained with PE anti-CD54 exhibited significant CD54 expression compared to the unstained 
control (Figure 1B). Nearly 100% of cells were CD54-positive, but expression did not differ 
significantly between naïve and activated cells. Additionally, a resazurin assay indicated no 
differences in cell metabolic activity between naïve versus primed/activated cells (Supplemental 
Figure 4). These results suggest that treatment with media versus TNF- α and PLP over a 24 hour 
period did not lead to significantly altered levels of cell activation.  
3.3 Flow Cytometry Binding Studies: Association and Competitive Dissociation 
 Flow cytometry association and competitive dissociation studies evaluated maximum 
steady state binding and specific binding, respectively. Figure 2 shows binding curves and 
associated binding values with homopolymers to illustrate how these studies were carried out 
and interpreted. Initial evaluation of fHA, fHAPLP, and fHALABL binding in naïve B cells showed 
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that fHAPLP exhibited the highest amount of binding at equilibrium, while both fHAPLP and 
fHALABL exhibited significantly higher binding than fHA (Figure 2AB). Specific binding of fHA, 
fHAPLP, and fHALABL was determined through competitive dissociation by addition of excess 
unlabeled HA, PLP, and LABL, respectively. Specific binding was evaluated as the difference 
between maximum steady state (SSmax) and dissociation steady state (SSns), which represented 
nonspecific binding (Figure 2B): 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝐵𝑖𝑛𝑑𝑖𝑛𝑔 =   𝑆𝑆!"# − 𝑆𝑆!"    (Equation 1) 
Both fHAPLP and fHALABL exhibited significantly higher specific binding than fHA. Percent (%) 
dissociation was evaluated as the amount of dissociation relative to maximum steady state 
binding, calculated as follows (Figure 2C): 
   %  𝐷𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 =    !!!"#!!!!"
!!!"#
     (Equation 2) 
This value provides the relative amount of maximum binding that is attributed to specific 
binding. Approximately 60% of the binding sites occupied by fHAPLP and fHALABL at 
equilibrium were dissociated after addition of unlabeled PLP or LABL, respectively, while 
approximately 40% of the binding sites occupied by fHA at equilibrium were dissociated after 
addition of unlabeled HA. Significantly higher specific binding took place with fHAPLP and 
fHALABL compared to fHA. Thus, HA displaying multiple copies of PLP or LABL peptide 
exhibited both increased binding and increased specificity of binding with B cells compared to 
the polymer alone.  
 Binding of fHA, fHAPLP, fHALABL, and fSAgAPLP:LABL was also evaluated separately in 
naïve and activated cells (Figure 3). Kinetic binding curves show fSAgAPLP:LABL exhibited the 
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fastest and highest amount of binding in Raji B cells (Figure 3A). In naïve and activated cells, 
fSAgAPLP:LABL exhibited a significantly higher SSmax compared to fHAPLP, fHALABL, and fHA 
(Figure 3B). Minimal differences in SSmax were expected in activated cells compared to naïve 
cells since there was a negligible change in CD54 and CD44 expression levels. However, the 
difference in SSmax of fSAgAPLP:LABL compared to fHAPLP and fHALABL was more statistically 
significant in activated cells (p<0.001) than in naïve cells (p<0.05). Displaying both peptides, 
PLP and LABL, on the fSAgAPLP:LABL heteropolymer array significantly enhanced binding 
compared to displaying multiple copies of one of these peptides on HA.  
Specific binding was evaluated for fHA, fHAPLP, and fHALABL in naïve and activated 
cells, revealing similar trends (Figure 3C). In naïve cells, fHAPLP and fHALABL exhibited 
significantly higher specific binding than fHA. In activated cells, fHAPLP exhibited significantly 
higher specific binding than fHA; no significance was detected when fHALABL was compared to 
fHA. As negligible differences were observed in activation levels, maximum binding, and 
specific binding between activated versus naïve cells, the remaining results herein include only 
naïve cells. 
Competitive dissociation of fSAgAPLP:LABL by excess addition of unlabeled components 
(HA, PLP, or LABL) was evaluated to determine the component of fSAgAPLP:LABL primarily 
responsible for binding (Figure 4). Percent dissociation (Equation 2) was evaluated for HA, PLP, 
LABL, OVA nonspecific peptide control, and media (Figure 4B). Dissociation caused by OVA, 
a nonspecific peptide included as a control for selectivity, was comparable to that caused by 
media, a control included to show dissociation by dilution and the resulting shift in equilibrium. 
In contrast, dissociation by LABL was significantly greater than that by media (p<0.01) and 
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OVA (p<0.05), while dissociation by PLP was significantly greater than that by media and OVA 
(p<0.001) and HA (p<0.01). These results indicate specificity with the LABL and PLP peptides. 
To determine % specific binding, % dissociation by the media control was subtracted 
from % dissociation by PLP, LABL, and HA to account for dissociation due to dilution (Figure 
4C): 
%  𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝐵𝑖𝑛𝑑𝑖𝑛𝑔!",!"!,!"  !"#! = %  𝐷𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛!",!"!,!"  !"#! −%  𝐷𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛!"#$% 
(Equation 3) 
PLP exhibited the highest % specific binding followed by LABL, and both were significantly 
higher than HA. Relative to the maximum equilibrium binding of fSAgAPLP:LABL, PLP was 
responsible for ~20% binding, LABL for ~13%, and HA for ~2%. Addition of PLP or LABL to 
naïve cells with bound fSAgAPLP:LABL caused significantly higher % dissociation than addition of 
HA. Thus, binding specificity of fSAgAPLP:LABL was attributed to both peptides, PLP and LABL, 
and was largely driven by PLP. 
3.4 Fluorescence Microscopy Using a Microfluidics Platform 
  Fluorescence microscopy of binding with Raji B cells was performed using a 
microfluidics platform (CellASIC Onix) in order to control perfusion of fluorescent samples and 
media rinse into the cell environment and capture images of binding in real time. Images show 
cell membrane localization of fHA (Figure 5A), fHALABL (Figure 5B), fHAPLP (Figure 5C), and 
fSAgAPLP:LABL (Figure 5D) from 0 to >10 minutes. Regions of heightened, punctate fluorescence 
intensity were observed on the surface of the cells, suggesting that binding and subsequent 
receptor clustering were taking place. Fluorescence on the surface of the cell was characterized 
as diffuse, punctate, or fully punctate (Figure 6A). Punctate staining was defined by multiple 
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areas of discrete high intensity fluorescence totaling <50% of the cell surface; fully punctate 
staining was defined by one predominant area of discrete high intensity fluorescence totaling 
<50% of the cell surface.  Progression from diffuse FITC fluorescence (0-5 min) towards fully 
punctate fluorescence on the cell surface (>10 min) was indicative of progressive receptor 
clustering following binding, which was observed most significantly in fSAgAPLP:LABL (Figure 
5D) but also to a lesser extent in fHALABL (Figure 5B) and fHAPLP (Figure 5C).  
 Percent (%) punctate positive cells was determined quantitatively across FITC positive 
cells for each treatment group and time interval (Figure 6B). Of the punctate positive cells, fully 
punctate cells were also distinguished (Figure 6C). Similar trends were observed in % punctate 
positive cells across samples and time intervals (Figure 6B), but differences were observed in % 
fully punctate cells (Figure 6C). Although fHA exhibited slightly higher % punctate positive 
cells compared to other samples, % fully punctate cells remained low and unchanged with time, 
whereas fSAgAPLP:LABL exhibited a steep increase in % fully punctate cells and the highest 
relative amount of fully punctate cells >10 minutes (Figure 6C). Comparing % fully punctate vs. 
% punctate cells, fSAgAPLP:LABL exhibited the greatest slope followed by fHALABL,  while fHA 
exhibited a near-zero slope (Figure 6D). Thus, of the punctate positive cells, fSAgAPLP:LABL 
induced the most rapid progression and highest amount of fully punctate fluorescence. 
3.5 Calcium Flux Signaling Flow Cytometry Assay 
Flow cytometry calcium flux was used to assay cellular response to SAgAPLP:LABL 
binding in anti-IgM-stimulated cells. Response was evaluated in Fluo-4 loaded Raji B cells after 
stimulation (Figure 7AB) and prior to stimulation (Figure 7CD) with crosslinking anti-IgM. 
Signaling kinetics show an abrupt reduction in signaling from addition of SAgAPLP:LABL, HAPLP, 
and HALABL, but negligible change from baseline after addition of vehicle (HBSS) or HA (Figure 
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7A). The relative signal reduction from stimulated baseline was determined using mean values at 
steady state. HAPLP, HALABL, and SAgAPLP:LABL exhibited significantly greater reduction in 
signaling than HA (Figure 7B) (p<0.0001), while HAPLP (p<0.05) and SAgAPLP:LABL (p<0.001) 
exhibited significantly greater reduction in signaling than HALABL. Signal reduction was not 
observed in non-stimulated cells (Supplemental Figure 3). Furthermore, SAgAPLP:LABL was 
effective at inhibiting anti-IgM stimulation (p<0.05) compared to the vehicle (Figure 7CD). It is 
important to note the reduction in calcium signaling was not accompanied by a reduction in cell 
metabolic activity, as indicated by a resazurin cell metabolic assay (Supplemental Figure 4). 
3.6 IgM Blocking 
 fSAgAPLP:LABL binding following blocking of the BCR by anti-IgM was evaluated by 
flow cytometry to provide further context to the calcium flux studies (Figure 7EF). Blocking 
with anti-IgM reduced fSAgAPLP:LABL maximum steady state binding by over 50%, from 
1.38x109 a.u (arbitrary fluorescence units) to 7.10x108 a.u. fSAgAPLP:LABL binding was 
significantly inhibited following IgM blocking (p<0.0001), suggesting that BCR is a target for 
fSAgAPLP:LABL binding. This result corroborates the calcium flux data, indicating that 
SAgAPLP:LABL binding dampens BCR-mediated signaling. 
4. Discussion 
Multivalent polymeric antigen arrays (i.e. many copies of an antigen epitope) have 
emerged as a promising option for ASITs with potential to modulate the immune response to 
specific, disease-causing autoantigens. 49, 50 Compared to monovalent antigen, multivalent 
antigens have been found to exhibit superior binding avidity, higher ‘effective concentration’, 
and an enhanced ability to activate or regulate cells. 11, 51-54 This concept has long been utilized in 
vaccine design to elicit strong antigen-specific immune responses. More recent studies have 
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suggested that tailoring multivalent array properties such as polymer or particle size, flexibility, 
antigen valency, and antigen spacing may direct the immune response towards tolerance versus 
immunogenicity. 32, 33, 55-60 Furthermore, these arrays provide an efficient platform for co-
delivery of two signals (primary antigen and secondary signal), which many believe to be 
essential for induction of an antigen-specific immune response. For example, incorporation of a 
costimulatory or inhibitory secondary signal may skew the immune response towards 
immunogenicity or tolerance of antigen, respectively. 24, 50, 61-66 
Extrapolating from this rationale, SAgAPLP:LABL molecules are designed to engage cell 
surface receptors to modulate antigen-specific signaling by incorporating multiple copies of 
autoantigen (PLP) and inhibitory signal (LABL). PLP autoantigen may target antigen-specific 
receptors such as the BCR or perhaps MHCII on autoreactive APCs that are involved in antigen-
specific signaling pathways. 67-69 The secondary LABL peptide is derived from LFA-1, an 
adhesion molecule present on T cells that engages ICAM-1 on APCs to provide a secondary 
context signal. 18, 44 LFA-1/ICAM-1 interaction promotes cell adhesion during signaling, so in 
addition to directing the immune response to PLP antigen, LABL may enhance B cell binding. 22-
24, 70-72 The HA polymer backbone is believed to act as a carrier to facilitate spatial and temporal 
co-delivery of PLP and LABL. The MW of HA was selected to direct transport as a function of 
its MW, as molecules greater than 16 kDa are likely to preferentially drain into the lymphatics 
following subcutaneous injection. 73-77 HA may also affect the ability of multivalent PLP and/or 
LABL to engage and cluster receptors. 31, 32, 49  
Our results showed significant ICAM-1 expression and minimal CD44 expression in both 
naïve and activated cells. Negligible differences in expression of either cell surface marker 
between the naïve and activated cells implied that treatment with TNF-α and PLP over 24 hours 
	  
	   106	  
did not cause a significant increase in activation levels. High expression of ICAM-1 in naïve 
cells suggests the cells persist in an inherently activated state, perhaps because Raji B cells are 
positive for Epstein-Barr virus (EBV). 78 EBV activates B cells and persists as a latent infection, 
causing differentiation into memory B cells. Increasing evidence also implicates EBV in the 
pathogenesis of MS, which may contribute to MS as a result of cross-reactivity between EBV 
and myelin antigens. 79-84 Molecular mimicry between these antigens was reported to cause 
cross-recognition between EBV- and myelin-specific B and T cells. 82, 85-92 These reports may 
provide an explanation for the insignificant differences in binding between naïve and activated 
Raji B cells. Naïve Raji B cells may exhibit significant specific binding with the PLP antigen due 
to cross-reactivity between EBV and myelin antigens. 
Flow cytometry studies showed inclusion of peptides, PLP or LABL, on the HA 
backbone increased binding of the polymer array with B cells (Figure 2). Incorporation of both 
PLP and LABL signals on the HA backbone, however, procured a cooperative effect and 
significantly increased B cell binding beyond that observed with the homopolymers (Figure 3). 
These results correlate with previous observations of in vivo EAE therapeutic efficacy, in which 
SAgAPLP:LABL alleviated disease while HAPLP, HALABL, and HA did not. 37 Therefore, enhanced 
binding with B cell APCs may be a main mechanism for the previously observed SAgAPLP:LABL 
therapeutic effect. 36, 37, 65, 93, 94 
Enhanced binding is desired for producing a strong immune response, but specific 
binding is thought to be critical for producing an antigen-specific response. Incorporation of 
peptides onto the HA backbone significantly increased specific binding of homopolymers 
(Figure 3), as evidenced by competitive dissociation by flow cytometry. Evaluation of specific 
binding with SAgAPLP:LABL revealed that both PLP and LABL contributed significantly to 
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specific binding compared to HA, but specific binding was primarily driven by PLP (Figure 4). 
Binding specificity dominated by PLP supports our hypothesis that SAgAPLP:LABL targets cells in 
an antigen-specific manner. 
Fluorescence microscopy images confirmed binding of the polymer arrays on the cell 
membrane and visible areas of heightened punctate fluorescence intensity provided evidence for 
receptor clustering. Receptor clustering in B cells (i.e. of BCR and ICAM-1) has been 
recognized as a marker for cell receptor engagement, signaling, and subsequent cellular 
activation. 31, 52, 70, 95-97 In fact, a proposed mechanism for the induction of a strong immune 
response by multivalent antigen is the ability of this antigen presentation format to sufficiently 
engage and cluster receptors, thereby initiating a cellular response. 24, 32, 54, 98 A minimum 
valency of 20 appropriately spaced antigens was proposed by Dintzis and others in 1976 to 
sufficiently engage and cluster a unit of receptors, forming an “immunon” capable of initiating 
response. 32  
The fluorescence microscopy images resemble those of others showing specific, localized 
receptor clustering in B cells (Figure 5). 31, 70, 99 Furthermore, the microfluidics platform allowed 
unique observation of sensitive changes in cell surface binding and receptor clustering behavior 
with time. Cell surface fluorescence was characterized as diffuse, punctate, or fully punctate, 
where degree of punctate fluorescence was indicative of the extent of receptor clustering (Figure 
6A). Interestingly, fSAgAPLP:LABL exhibited the highest relative amount of fully punctate cells 
with time – that is, of the increasing number of punctate positive cells, most were fully punctate 
(i.e., exhibited one discrete area of fluorescence) (Figure 6C). In contrast, fHA exhibited an 
unchanged amount of fully punctate positive cells with time. These results suggest that 
fSAgAPLP:LABL induced more developed, mature receptor clustering as compared to the 
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homopolymers, while clustering induced by fHA did not fully develop with time. Furthermore, 
the steep slope of % fully punctate vs. % punctate cells for fHALABL was most similar to the trend 
observed for fSAgAPLP:LABL, suggesting that LABL, rather than PLP, may drive fully developed 
receptor clustering (Figure 6D). An integral role of LABL in receptor clustering is consistent 
with evidence that LFA-1/ICAM-1 interactions promote cell adhesion and signaling. 70 
Similarly, our results corroborate observations of increased localized density of ICAM-1 on the 
surface of B cells during signaling and activation. 97 These imaging observations therefore 
provide complementary insight into the SAgAPLP:LABL cellular mechanism: while PLP drives 
crucial antigen-specific binding, LABL may drive receptor clustering to facilitate a stronger 
cellular response. 
Valency-induced receptor clustering and localization in B cells has been correlated with 
increased calcium signaling, which is a key marker for cellular response following antigen-
specific binding. 31, 100, 101 However, receptor engagement and clustering can also induce a robust 
tolerogenic or inhibitory response. 49 For example, it has been shown that engagement and 
clustering of BCR with an inhibitory co-receptor can cause inhibition of B cell activation. 61 
Indeed, our calcium flux results showed that SAgAPLP:LABL induced an abrupt reduction in IgM-
stimulated signaling in Raji B cells, while pretreatment with SAgAPLP:LABL was capable of 
significantly inhibiting IgM stimulation. Furthermore, fSAgAPLP:LABL binding was significantly 
inhibited following IgM blocking, suggesting that BCR is a target for the fSAgAPLP:LABL 
molecule and corroborating the competitive dissociation data showing specific PLP binding. 
Taken together, these results indicate that SAgAPLP:LABL binding dampens BCR-mediated 
signaling. 
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In comparison to SAgAPLP:LABL, HAPLP and HALABL had less effect on calcium signaling, 
and HA did not cause a significant change. While the time scales are different between the 
calcium flux experiment (0-5 minutes) and the fluorescence microscopy binding experiment (0-
5, 5-10, >10 minutes), it is notable that HA, which did not exhibit an increase in ‘fully punctate’ 
binding, also did not induce a change in calcium flux. Thus, our results suggest that progression 
to ‘fully punctate’ binding correlated with a greater reduction in calcium flux. 
 
5. Conclusions 
Results reported here offer a therapeutic mechanism to support previously reported in 
vivo observations, which indicated that co-presentation of both signals on HA was necessary for 
therapeutic efficacy. SAgAPLP:LABL co-presentation of PLP autoantigen and LABL cell adhesion 
inhibitor resulted in greatly enhanced B cell binding in vitro compared to HA arrays presenting 
only one signal. Furthermore, SAgAPLP:LABL exhibited specific binding that was increased by the 
presence of both peptides and largely driven by the antigenic PLP peptide, supporting our 
hypothesis that SAgAPLP:LABL acts in an antigen-specific manner. While the primary antigen PLP 
drives specific binding, the secondary signal LABL appears to play an important role in 
progressing to fully developed receptor clustering. SAgAPLP:LABL progressed to fully punctate 
receptor clustering to a greater extent than HA, HAPLP, or HALABL, which correlated with greater 
reduction in BCR-mediated calcium signaling. In addition to elucidating SAgAPLP:LABL cellular 
mechanisms, the methods developed in these studies lay the foundation to further investigate 
design criteria for specific-targeting immunotherapies and progress towards safer and more 
effective treatments for autoimmune disease. 
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Table 1. Peptide molar conjugation was determined by reverse-phase HPLC and results are an 
average of triplicate injections from a single batch preparation.  
Sample Approx. MW (kDa)a 




PLP:HA LABL:HA PLP LABL 
fHA 16.6  0 0 0 0 
fHAPLP 
 
30.4  9 0 21 0 
fHALABL 
26.0  0 10 0 24 
fSAgAPLP:LABL 
46.3 10 13 24 31 
a Calculated from RP-HPLC data. MW, molecular weight. 
b HA, hyaluronic acid; PLP, proteolipid protein peptide; LABL, inhibitor peptide derived from 
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Figure 1. Activation marker expression in Raji B cells observed by flow cytometry: A) CD44 
and B) CD54 (ICAM-1) expression is shown through representative histograms, % positive cells, 
and mean fluorescence intensity (MFI) of FITC anti-CD44 or PE anti-CD54 stained samples, 
respectively. Naïve cells were untreated (incubated in media) while primed/activated cells were 
stimulated with TNF-α and primed with PLP for 24 hours. Cells exhibited minimal expression of 
CD44 but significant expression of CD54. Primed/activated cells and naïve cells showed similar 
expression of CD44 and CD54. (n=3) 
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Figure 2. Association, dissociation, and specific binding of homopolymers in naïve Raji B cells 
determined by flow cytometry. A) Kinetic binding curves show association of fHA, fHALABL, 
and fHAPLP carried out until maximum steady state (SSmax) was reached, followed by 
competitive dissociation (arrow) through addition of excess unlabeled HA, LABL, or PLP, 
respectively. The final steady state following dissociation represents nonspecific binding (SSns). 
B) SSmax binding and specific binding (calculated from the difference between SSmax and SSns, 
Equation 1) for each sample from A. C) Percent (%) dissociation was determined from specific 
binding relative to SSmax binding (Equation 2). Statistical significance determined by ANOVA 
followed by Tukey’s post-hoc test with p<0.05 (n=3). Robust curve fitting in A was performed 
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Figure 3. Binding of fSAgAPLP:LABL in naïve and primed/activated Raji B cells determined by 
flow cytometry: A) Kinetic binding curves show association of fHA, fHALABL, fHAPLP, and 
fSAgAPLP:LABL in primed/activated Raji B cells. B) Maximum steady state (SSmax) binding of 
fHA, fHALABL, fHAPLP, and fSAgAPLP:LABL determined from association. C) Specific binding of 
fHA, fHALABL, and fHAPLP determined from competitive dissociation with excess unlabeled HA, 
LABL, or PLP, respectively. Primed/activated cells were stimulated with TNF-α and primed 
with PLP for 24 hours. Statistical significance determined by ANOVA followed by Tukey’s 
post-hoc test with p<0.05 (n=3). Robust curve fitting in A was performed using sigmoidal 
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Figure 4. Specific binding of fSAgAPLP:LABL in naïve Raji B cells determined by flow cytometry 
competitive dissociation: A) Representative kinetic scatter plots of FITC fluorescence varying 
with time, showing three separate runs of fSAgAPLP:LABL association followed by competitive 
dissociation with HA, LABL, or PLP. B) Percent (%) dissociation from competition with media 
control, OVA nonspecific peptide control, HA, LABL, or PLP, determined from specific binding 
relative to maximum steady state (SSmax) binding. C) Percent (%) specific binding determined 
from dissociation with HA, LABL, and PLP (subtracting dissociation from media control, 
Equation 3). Statistical significance determined by ANOVA followed by Tukey’s post-hoc test 
with p<0.05 (n=3). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
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Figure 5. Fluorescence microscopy showing real-time fSAgA binding with live Raji B cells 
following perfusion of A) fHA, B) fHALABL, C) fHAPLP, and D) fSAgAPLP:LABL. Following 
perfusion of treatment groups into the cell mixing chamber for 5 minutes and gentle media 
perfusion for an additional 5 minutes to rinse, images were captured from (t=0) across time 
intervals of [0-5), [5-10), and >10 minutes. Images show cells stained with Hoechst (violet) and 
FITC-labeled samples (green). Progression from diffuse FITC fluorescence (0-5 min) towards 
punctate FITC fluorescence on the cell surface (>10 min) suggests progressive receptor 
clustering resulting from fSAgA binding. Captured using the M04S plate and CellASIC Onyx 
Microfluidics platform on an Olympus IX81 inverted Epifluorescence microscope. 
Magnification: 60X Air. Exposure: Hoechst (exc. 384 nm) 125 ms, FITC (exc. 484 nm) 3000 ms. 
Scale bar equals 10 µm.  
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Figure 6. Analysis of progressive receptor clustering in Raji B cells following fSAgA binding 
was determined by fluorescence microscopy. A) Characteristic examples of diffuse, punctate, or 
fully punctate cell surface binding in Raji B cells are shown. Punctate staining was defined by 
multiple areas of discrete high intensity fluorescence totaling <50% of the cell surface; fully 
punctate staining was defined by one predominant area of discrete high intensity fluorescence 
totaling <50% of the cell surface. Images show cells stained with Hoechst (violet) and FITC-
labeled samples (green). Scale bar equals 10 µm. B) Percent (%) punctate positive cells was 
determined across FITC positive cells for each treatment group per time interval. For each 
sample and time interval, several fields were randomly selected and 40–200 FITC positive cells 
total were counted and scored for diffuse versus punctate staining. C) Of the punctate positive 
cells, fully punctate cells were also distinguished. D) Percent (%) fully punctate versus % 
punctate cells shows the greatest slope for fSAgAPLP:LABL and a near-zero slope for fHA. 
Composite analysis from two independent experiments. 
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Figure 7. IgM-stimulated (BCR-mediated) signaling response was evaluated in Raji B cells 
through flow cytometry calcium flux. A) Reduction: Fluo-4 loaded cells were stimulated with 
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anti-IgM (αIgM) at 50 s, then treated with an addition of vehicle (HBSS), HA, HAPLP, HALABL, 
or SAgAPLP:LABL at ~120 s (black arrow) to evaluate signaling reduction. Kinetics show median 
Fluo-4 fluorescence values. B) Percent reduction from stimulated baseline caused by addition of 
samples in figure A, determined from mean steady state values. C) Inhibition: Fluo-4 loaded 
cells were first pre-treated with an addition of vehicle (HBSS) or SAgAPLP:LABL, then stimulated 
with αIgM (black arrow) to evaluate signaling inhibition. D) Relative αIgM stimulation in 
signaling following pre-treatment with vehicle or SAgAPLP:LABL. Baseline-adjusted values 
determined from mean steady state values. E) Targeting: fSAgAPLP:LABL binding was evaluated 
by flow cytometry following blocking of BCR by αIgM. F) Maximum steady state (SSmax) 
binding of fSAgAPLP:LABL compared in Raji B cells following blocking by αIgM. Statistical 
significance determined by ANOVA followed by Tukey’s post hoc test (B) or unpaired t-test (D, 
F) with p<0.05 (n=3). Robust curve fitting (E) was performed using sigmoidal nonlinear 
regression. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
  
	  




Supplemental Figure 1. Flow cytometry histograms showing the gating protocol used to 
remove A) dead cells and B) debris from analysis. Scatter plots show C) ungated and D) live cell 
populations. QNuclear Red (or propidium iodide, PI) was used as a dead cell indicator and 
Hoechst was used as a nuclei stain. Plots generated in Kaluza Flow Analysis software.  
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Supplemental Figure 2. Flow cytometry histograms showing unstained controls, isotype 
controls, and positive stains for A) FITC-CD44 antibody labeling and B) PE-CD54 antibody 
labeling in Raji B cells.  
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Supplemental Figure 3. Flow cytometry calcium flux in Fluo-4 loaded Raji B cells shows A) no 
signaling change in non-stimulated cells upon addition of SAgAPLP:LABL (black arrow). Kinetics 
show median Fluo-4 fluorescence values. B) Fluo-4 signal from figure A determined from mean 
steady state values. 
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Supplemental Figure 4. Resazurin cell metabolic assay in naïve and primed/activated Raji B 
cells shows metabolic activity in response to 24 hour treatment with vehicle (media), HA, 
HALABL, HAPLP, or SAgAPLP:LABL. Statistical significance determined by two-way ANOVA 
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Chapter IV: Multivalent Antigen Arrays Exhibit High 
Avidity Binding and Modulation of B Cell Receptor-
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1. Introduction 
Autoimmune diseases such as multiple sclerosis (MS) are typified by a breakdown of 
healthy immune regulation and subsequent misrecognition of self for non-self. 1, 2 The 
autoimmune breakdown in MS is largely propagated by autoreactive T and/or B cell clonal 
expansion and attack against myelin sheath autoantigens, leading to demyelination and 
neurodegeneration. 3-6 Activation of naïve T cells against autoantigen requires two signals from 
an antigen presenting cell (APC): (1) primary antigenic signal delivered through the major 
histocompatibility complex (MHC) on the APC to the T cell receptor (TCR) on the T cell, and 
(2) secondary costimulatory signal (i.e., CD80/CD86) delivered to the conjugate receptor (i.e., 
CD28) on the T cell. 7-15 B cells, as professional APCs that possess antigen specificity and 
immunological memory, play a particularly pivotal role in immune regulation. 16-18 Indeed, loss 
of B cell tolerance has been implicated in numerous autoimmune diseases. 19-21 B cell 
autoimmune therapies have been successful in the clinic (i.e., ritixumab), but general B cell 
depletion or inactivation may induce global immunosuppression, may trigger adverse side 
effects, and may suffer from limited efficacy. 22-24 Development of antigen-specific 
immunotherapy (ASIT) that targets and silences autoreactive B cells in a selective manner would 
address an important need for safer and more effective treatment. 25-27  
Modulation of B cells in a direct, antigen-specific manner requires targeting of the B cell 
receptor (BCR). 18 Antigen binding to the BCR can trigger receptor clustering and antigen-
specific B cell activation. 28-32 However, continuous antigen binding and occupation of the BCR 
in the absence of secondary costimulatory signals results in B cell anergy, or a state of antigen 
unresponsiveness, that is marked by reduced calcium signaling and down-regulation of 
costimulatory markers such as CD80/CD86. 27, 33-35 Similarly, costimulatory signal presentation 
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by APCs is essential for autoreactive T cell activation; reception of the primary antigenic signal 
in the absence of secondary costimulatory signal leads to T cell anergy. 15, 25, 26, 36 Induction of B 
cell anergy can therefore have a two-fold therapeutic effect by inducing (1) an effector B cell 
population that is not responsive to autoantigen and (2) B cells with reduced APC capacity. 
Thus, a promising avenue for modulating the immune response in an antigen specific manner is 
to induce these B cell phenotypes through BCR engagement.  
Multivalent linear polymers are especially adept at engaging cell surface receptors such 
as the BCR. 30, 37-43 We previously reported on multivalent soluble antigen arrays (SAgAPLP:LABL) 
consisting of a linear hyaluronic acid (HA) polymer co-grafted with myelin autoantigen peptide 
(proteolipid protein peptide, PLP139-151) and intracellular adhesion molecule-1 (ICAM-1) 
inhibitor peptide derived from leukocyte function associated antigen-1 (LFA-1), known as 
LABL. 44-50 SAgAPLP:LABL exhibited antigen-specific binding with B cells, targeted the BCR, and 
dampened BCR-mediated signaling. 44 Treatment with SAgAPLP:LABL in vivo significantly 
alleviated experimental autoimmune encephalomyelitis (EAE), a murine model of relapsing-
remitting multiple sclerosis. 46-50 Here, we have developed a new version of the SAgA molecule, 
termed ‘click SAgA’ (cSAgAPLP:LABL), using click conjugation rather than hydrolyzable grafting 
of multivalent PLP and LABL peptides to HA using a hydrolyzable oxime bond. We explore 
whether this non-hydrolyzable conjugation chemistry will improve B cell engagement and 
modulation of BCR-mediated signaling, and if in vivo efficacy is correspondingly improved. 
B cell binding, signaling, and therapeutic efficacy in EAE were compared between 
SAgAPLP:LABL (oxime conjugation chemistry) and cSAgAPLP:LABL (‘click’ conjugation chemistry) 
through a combination of in vitro and in vivo studies. Binding avidity was evaluated in 
immortalized human Raji B cells as a model APC system using flow cytometry binding assays 
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developed previously. 44 Modulation of BCR-mediated signaling was assessed using flow 
cytometry calcium flux assays. Engagement and organization of BCR on the cell surface was 
observed through real-time fluorescence microscopy. Lastly, in vivo efficacy was compared 
across various doses in the EAE model.  
 
2. Materials and Methods 
2.1 Materials 
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore 
Biomedical (Chaska, MN). Aminooxy-LABL (AoLABL, Aoa-itDGEATDSG-OH), aminooxy-
PLP (AoPLP, Aoa-HSLGKWLGHPDKF-OH), and PLP (NH2-HSLGKWLGHPDKF-OH) 
peptides were purchased from PolyPeptide Laboratories (San Diego, CA). 11-azido-3,6,9-
trioxaundecan-1-amine (NH2-PEG3-N3), N-hydroxysuccinimide, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), 2-(N-morpholino)ethane-sulfonic acid sodium salt 
(MES), tris(3-hydroxypropyltriazolylmethyl)amine, and sodium ascorbate (NaAsc) were 
purchased from Sigma-Aldrich (St. Louis, MO) and used as received without further 
purification.  Copper(II) sulfate pentahydrate (CuSO4 • 5H2O) was purchased from Acros 
Organics (Geel, Belgium). Alkyne-functionalized peptides bearing an N-terminal 4-pentynoic 
acid (homopropargyl, hp) modification were originally synthesized in our laboratory via solid 
phase peptide synthesis, but larger quantities of both hpPLP139-151 and hpLABL peptides were 
obtained from Biomatik USA, LLC (Wilmington, DE). Incomplete Freund’s adjuvant (IFA) and 
killed Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, MD). 
Pertussis toxin was purchased from List Biological Laboratories (Campbell, CA). Fluorescein 
isothiocyanate (FITC) and Fluo-4 AM calcium indicator were purchased from Thermo Fisher 
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Scientific (Waltham, MA). Immortalized human Raji B cells were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). AffiniPure F(ab’)2 fragment goat anti-human 
IgM and AlexaFluor 647 AffiniPure F(ab’)2 fragment goat anti-human IgM were purchased from 
Jackson ImmunoResearch Laboratories (West Grove, PA). All other chemicals and reagents 
were analytical grade and used as received. 
2.2 SAgA Synthesis and FITC Labeling 
To synthesize SAgAs, HA was grafted with aminooxy peptides AoPLP and/or AoLABL 
as previously described to make HAPLP (HA and AoPLP), HALABL (HA and AoLABL), and 
SAgAPLP:LABL (HA, AoPLP, and AoLABL). 47 HA was dissolved (2 mg/ml) in a 20mM acetate 
buffer at pH 5.5, then combined with respective peptide(s) to achieve a target conjugation 
efficiency per peptide of 25% (or approximately 10 of each peptide per fHA backbone). Solution 
pH was readjusted to pH 5.5 and stirred at 400 rpm for 24 hours. Samples were dialyzed in d.d. 
H2O (100X volume) to remove free peptides using 6000-8000 MWCO regenerated cellulose 
dialysis tubing over 24 hours with a total of 4 washes, then frozen and lyophilized. 
To synthesize FITC-labeled SAgAs (fSAgAs), HA (16 kDa) was first reacted with FITC 
to make labeled HA-FITC (fHA). 51 HA was gently dissolved in d.d. H2O (5 mg/ml), then 
combined with an equal volume of DMSO containing sodium bicarbonate (2.5 mg/ml), 
dibutyltin dilaurate (3.96 mM), and FITC (6 mg/ml). The reaction mixture was heated in an oil 
bath at 50°C for 30 minutes while stirring at 70 rpm, then quenched by drop-wise addition to 
cold ethanol (17.5X volume). Dialysis took place in d.d. H2O (100X volume) to remove free 
FITC using 3500 MWCO regenerated cellulose dialysis tubing (Spectrum Laboratories, Rancho 
Dominguez, CA), rinsing every 6-12 hours for a total of six washes. The fHA solution was then 
frozen and lyophilized. Peptide conjugation with fHA was performed as detailed above to make 
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fHAPLP, fHALABL, and fSAgAPLP:LABL. All fHA synthesis and subsequent handling was 
performed under protection from light. 
2.3 SAgA and FITC-SAgA Analytical Characterization 
Peptide conjugation of each sample was determined through gradient reverse-phase 
analytical high-performance liquid chromatography (RP-HPLC) (Waters Corp., Milford, MA) on 
a C18 analytical column (Higgins Analytical, Proto200, 5 µm, 200 Å, 250 x 4.6 mm2, Mountain 
View, CA) following cleavage of peptides in 0.1N HCl. Samples were compared to standard 
curves of AoPLP and AoLABL to determine peptide content. A gradient method using aqueous 
mobile phase A (94.9% d.d. H2O, 5% acetonitrile, 0.1% trifluoroacetic acid (TFA)) and organic 
mobile phase B (99.9% acetonitrile, 0.1% TFA) was used to analyze samples. Samples were 
detected at 220 nm. 
Relative FITC fluorescence of labeled samples was determined spectrofluorometrically 
on a fluorescent plate reader (SpectraMax M5e, Molecular Devices, Sunnyvale, CA). A 
fluorescence calibration curve was generated for each sample ranging from 0 to 0.5 mg/ml, and 
the relative fluorescence intensity (f) was determined in the linear region of the calibration curve 
at 0.4 µM relative to fHA (fHA=1). The relative fluorescence intensity of each test article was 
used to normalize flow cytometry FITC fluorescence.  
2.4 Click-conjugated ‘cSAgA’ Synthesis and PennGreen Labeling 
2.4.1 Synthesis of HA-N3 
Synthesis of HA-N3 was adapted from Hu et al and Di Meo et al. 52, 53 Sodium 
hyaluronate (93.9 µmol, assumed 16 kDa average MW) was added to a 250 mL round bottom 
flask with stir bar, followed by 100 mL of 50 mM MES buffer (pH = 4.0). The mixture was 
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stirred until in solution (~15 min) before EDC (23.1 mmol) was added neat, then N-
hydroxysuccinimide (18.8 mmol) added neat. The mixture was stirred for 5 min before H2N-
PEG3-N3 (4.51 mmol) in 20 mL MES buffer was added. The solution was then stirred for 24 hr 
at room temperature before being dialyzed in 6-8 kDa cutoff dialysis tubing against 4.5 L of 1.0 
M NaCl solution for 24 hr, then 4.5 L of deionized water (4 x 12 hr). The volume in the bag was 
then transferred to vials, slow-frozen, and lyophilized to yield a white powder. Yield: 1.605 g 
(95.0%). (Refer to Scheme 1) 
2.4.2 Synthesis of cSAgA 
HA-N3 (2 µmol, assumed 20 kDa average MW) was added as a 50 µM solution in 
deionized H2O to a 250 mL round bottom flask with stir bar. Each component peptide (40 µmol) 
was then added as a ~3 µM solution in deionized H2O, followed by a premixed solution of 
THPTA (70 µmol) and CuSO4 • 5H2O (14 µmol) in deionized water. The solution was allowed to 
stir for 1-2 min before a 100 µL aliquot was removed for HPLC analysis. NaAsc (300 µmol) was 
then added to the reaction mixture as a 100 µM solution in deionized water. The reaction was 
allowed to proceed for 24 hrs at 55°C. Additional 100 µL aliquots were removed throughout the 
course of the reaction and analyzed by RP-HPLC to determine the extent of conjugation. Once 
target conjugation values were achieved, the reaction solution was transferred to 6-8 kDa dialysis 
tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 x 8 hr), then 4.5 L of deionized H2O (5 x 8 
hr). The volume in the bag was then transferred to vials, slow-frozen, and lyophilized to yield a 
white powder. (Refer to Scheme 2) 
2.4.3 Click-conjugated cSAgA Analytical Characterization 
FTIR spectra were collected on a Bruker Tensor 27 FTIR spectrometer equipped with an 
Attenuated Total Reflectance (ATR) cell, analyzing purified samples at ambient temperature in 
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the solid state, and collecting a total of 32 scans per sample.  NMR spectra were collected on a 
Bruker Avance AVIII 500 MHz spectrometer equipped with a dual carbon/proton cryoprobe, and 
all samples were dissolved in 650 µL of D2O for analysis.  RP-HPLC and SEC analysis were 
conducted using a Waters Alliance HPLC system equipped with either a diode array detector or 
dual wavelength UV/Vis detector.  For the quantitative determination of peptide conjugation by 








   Equation 1 
where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in 
reaction, nHA = moles of HA-N3 used in reaction, Vpre = total reaction volume before NaAsc is 
added, Vsam = volume of “pre-NaAsc” sample removed from reaction mixture, PAt = measured 
peak area of peptide at time t, PAstart = measured peak area of free peptide before NaAsc is added 
to the reaction.  General chromatographic conditions employed a Waters XBridge C4, 3.5 µm, 
300 Å stationary phase under ion pairing (0.05% TFA in H2O and MeCN) mobile phase 
conditions, utilizing a linear elution gradient (5-60%) with detection at 214 nm. 
2.5 Cell Culture  
Raji B cells (human B lymphocytes, ATCC) were cultured in RPMI-1640 supplemented 
with L-Glutamine, 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin (P/S) at 37°C 
and 5% CO2. Cell assays were consistently performed after cells reached confluency (~2 weeks) 
and following no more than 8-10 passages, per ATCC guidelines.  
2.6 Flow Cytometry Binding Assay 
Association binding studies were performed by flow cytometry (MoFlo XDP Cell Sorter, 
Beckman Coulter Inc., Brea, CA), as previously reported. 44 Cell nuclei were stained with 
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Hoechst and propidium iodide (PI) was used as a dead cell indicator; data acquisition was 
triggered off the Hoechst signal. Cell samples were warmed to 37°C for 2 minutes prior to the 
flow cytometry run. Fluorescence was excited using 488, 405, and 640 nm lasers and was 
collected using 529/28, 457/40, and 670/30 bandpass emission filters.  
To observe maximum steady state binding, cells were mixed with the treatment to 
achieve a final concentration of 1x106 cells/ml immediately before injecting on the flow 
cytometer. Sample concentration was determined from preliminary saturation studies. 44 Samples 
were added at an equimolar PLP dose (353.18 µM PLP for fHAPLP and fSAgAPLP:LABL, or 353.18 
µM LABL for fHALABL) and fHA was dosed at 39.19 µM (the HA molar equivalent to a 353.18 
µM PLP dose of fSAgAPLP:LABL) to mimic animal studies. The sample was allowed to run until 
maximum steady state was established.  
Flow cytometry binding data was first gated to remove doublets, dead cells, and debris 
using Kaluza Flow Analysis software (Beckman Coulter, Inc., Brea, CA) (Supplemental Figure 
1). Additional data processing was performed using KNIME software (Konstanz Information 
Miner, KNIME, Zurich, Switzerland). Nonlinear regression and additional statistical analysis 
was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).  
2.7 Calcium Flux Signaling Assay 
 Raji B cells were loaded with 5 µM Fluo-4 AM for 30 minutes at room temperature in 
PBS, then kept on ice in HBSS (Hanks Balanced Salt Solution) containing 1.3 mM Ca2+ and 0.9 
mM Mg2+ before analysis. Cells were run through a BD FACSFusion cytometer and 
fluorescence was monitored in the 530/30 channel. After baseline quantification for ~30 seconds, 
crosslinking goat anti-human IgM (Jackson ImmunoResearch) was added at 20 µg/ml to 
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stimulate the cells. Changes in Fluo-4 fluorescence were measured for 1 minute to establish an 
anti-IgM stimulated baseline, followed by addition of SAgA treatment (dosed at 353.18 µM PLP, 
same concentration used in binding studies) to determine the effect on IgM-stimulated signaling. 
Data was acquired for an additional 3 minutes until steady state was established. To measure 
inhibition of anti-IgM stimulation, cSAgAPLP:LABL was added to cells prior to anti-IgM 
stimulation. KNIME was used to process and plot the kinetic data, while Kaluza and GraphPad 
Prism were used for the remaining analysis.  
2.8 Fluorescence Microscopy 
Live cell imaging of fcSAgA binding and surface IgM clustering was observed under 
fluorescence microscopy (Olympus IX81 Inverted Epifluorescence Microscope) using the same 
concentrations from flow cytometry association binding experiments. CellASIC ONIX M04S 
Microfluidics Switching Plates and Microfluidics Platform (EMD Millipore, Billerica, MA) were 
utilized for controlled perfusion of fluorescent samples and media with cells during real-time 
imaging. Raji B cells were stained with Hoechst and mixed with AlexaFluor 647 goat anti-
human IgM (Jackson ImmunoResearch) at 20 µg/ml to stimulate the cells and label surface IgM, 
then loaded into the imaging chamber. fcSAgA was perfused into the chamber for 10 minutes (1 
psi for 5 minutes, 0.25 psi for 5 minutes) to allow binding with cells, followed by gentle media 
perfusion (0.25 psi for 5 minutes) to rinse unbound fcSAgA, followed by immediate image 
capture. Images were analyzed using Slidebook 5.5 (Intelligent Imaging Innovations, Inc., 
Denver, CO). 
2.9 Clinical EAE Study in Mice 
Animal studies were carried out with 4-6 week old SJL/J (H-2) female mice purchased 
from Envigo Laboratories (Indianapolis, IN). Mice were housed under specified, pathogen-free 
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conditions at The University of Kansas and all experiments were approved by the University’s 
Institutional Animal Care and Use Committee. Complete Freund’s adjuvant (CFA) was made by 
combining IFA and killed M. tuberculosis strain H37RA at a final concentration of 4 mg/ml. 
Animals were induced with experimental autoimmune encephalomyelitis (EAE), the PLP-
specific mouse model of relapsing-remitting MS, on day 0 of the study. Immunization was 
accomplished using a 0.2 ml emulsion containing 200 µg PLP139-151 peptide, plus equal volumes 
of PBS and CFA. The emulsion was administered subcutaneously (s.c.) as a total of four 50 µl 
injections, located above each shoulder and each hind flank. Pertussis toxin (100 ng in 100 µl) 
was injected intraperitoneally on day 0 and day 2 post-immunization. 
Treatments were administered on days 4, 7, and 10 as 100 µl subcutaneous injections at 
the nape of the neck (n=3-6 mice per treatment group), with the exception of one group in the 
dosing study that received treatments on days 4 and 7 only. Samples were administered at a dose 
equivalent to 50, 133, or 200 nmol PLP per 100 µl (0.5, 1.33, or 2 mM PLP, respectively). This 
three-day dosing schedule and dose of 200 nmol PLP were found to be efficacious in a previous 
SAgAPLP:LABL study. 49 Disease progression was evaluated by a single observer using the 
following clinical score system: 0, no clinical disease symptoms; 1, weakness or limpness of the 
tail; 2, weakness or partial paralysis of one or two hind limbs (paraparesis); 3, full paralysis of 
both hind limbs (paraplegia); 4, paraplegia plus weakness or paralysis of forelimbs; 5, moribund 
(at which point mice were euthanized). In addition to animal scoring, body weight measurements 
were performed daily for the 26-day duration of the EAE study. 
2.10 Statistical Analysis 
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test.  
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ANOVA was followed by Tukey’s or Sidak’s post-hoc test, where appropriate. The threshold for 
statistical significance was set to p<0.05. 
 
3. Results and Discussion 
3.1 cSAgA Structural Design 
 Previous soluble antigen arrays studied in our research group employed a hydrolyzable 
linker chemistry to conjugate both PLP and LABL peptides to HA, and have been shown to 
significantly suppress disease severity in EAE. 44-50 To evaluate the possibility that release of 
PLP or LABL encountered in vivo or in vitro may influence the observed efficacy of SAgA 
treatments, we synthesized click-SAgA (cSAgA) variants that exploit non-cleavable linker 
chemistry. The cSAgA multivalent arrays utilize the Copper-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) reaction as a stable attachment chemistry, which carries significant 
literature precedence with respect to application 54, 55 and optimization 56, 57. In addition to bond 
stability, the versatility of the CuAAC reaction was a major consideration in the implementation 
of an alternative conjugation chemistry, as the wide range of available reaction conditions can 
enable improved control over valency. 
3.2 cSAgA Analytical Characterization   
Characterization was completed using a variety of qualitative and quantitative analytical 
techniques. Initial azide-functionalization was confirmed by FTIR spectroscopy, showing the 
presence of a characteristic azide stretching band after synthesis of HA-N3, which disappeared 
following utilization of the azide moiety during conjugation (Figure 1). Quantitative analysis of 
peptide conjugation efficiency was conducted via RP-HPLC by measuring the decrease in peak 
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area of the free alkyne-containing peptide(s) after the reaction (Table 1). The CuAAC 
conjugation chemistry requires an active Cu1+ catalyst for the reaction to proceed, which is 
generated in situ through addition of the reducing agent NaAsc to an inactive Cu2+ in solution. 
Prior to this final NaAsc addition step, an aliquot of the reaction mixture is removed for HPLC 
analysis to establish a baseline response correlating to the stoichiometric peptide equivalents 
used in the reaction (Figure 2). Subsequent to the addition of NaAsc, any decrease in peak area 
of free alkyne-containing peptide can be attributed to conjugation. Standard curves for both 
peptides were linear to 110% of the nominal concentrations used in the reaction mixture (0.81 
mM for hpPLP139-151 and 0.71 mM for hpLABL), exhibiting R2 values >0.99 upon linear 
regression analysis. Additional control experiments showed both peptides displayed <5% 
degradation at 37°C in H2O over 20 hr in the absence of all other reaction components, 
indicating a minimal impact of peptide degradation on the accuracy of the analytical 
methodology. Quantitative peptide conjugation of representative test articles is provided in Table 
1, showing that target conjugation efficiencies of approximately 25% per peptide were achieved 
in cHAPLP (10 PLP), cHALABL (12 LABL), and cSAgAPLP:LABL (11 PLP, 9 LABL). 
NMR spectroscopy was used qualitatively to confirm the existence of resonances present 
in both peptide samples, which carried over to the final dialyzed product. Quantitation by 1H 
NMR proved challenging due to signal broadening of the increasingly heterogeneous polymeric 
systems, and the high molecular weight of the multivalent arrays leads to decreasing sensitivity 
with increasing conjugation, eventually limited by sample solubility. Figure 3 shows a 
representative analysis via Distortionless Enhancement by Polarization Transfer (13C DEPT-135) 
NMR spectroscopy where CH and CH3 resonances are out of phase with CH2 resonances, 
yielding signals in the final cSAgAPLP:LABL compound which are both present and in the correct 
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phase with the free component peptides. 1H/13C Heteronuclear Single Quantum Coherence 
(HSQC) NMR experiments also showed the disappearance of the terminal alkyne resonance 
from the linker on each peptide, with the concomitant appearance of a broadened aromatic 
resonance not present in any individual component. 
3.3 SAgA Analytical Characterization 
SAgAs and fSAgAs were analyzed by RP-HPLC to determine molecular weight and 
peptide conjugation, as described previously. 47 Quantitative peptide conjugation of 
representative test articles is provided in Table 1, showing that target conjugation efficiencies of 
approximately 25% per peptide were achieved in HAPLP (9 PLP), HALABL (10 LABL), and 
SAgAPLP:LABL (10 PLP, 13 LABL). 
3.4 Flow Cytometry Binding Assay 
A flow cytometry binding assay was used to compare the relative binding avidities of 
hydrolyzable fSAgA and click-conjugated fcSAgA with Raji B cells. Binding kinetics were 
observed during association between the fluorescently labeled polymer arrays and Raji B cells 
until maximum steady state (max. SS) was reached, illustrated in Figure 4A. It was previously 
observed that fSAgAPLP:LABL, co-grafted with both PLP and LABL, exhibited greater binding 
with Raji B cells than the polymer alone (fHA) or the homopolymers grafted with only one 
signal (fHAPLP or fHALABL). 44 A similar trend was observed with click-conjugated arrays: 
fcSAgAPLP:LABL exhibited the highest amount of binding, followed by fHAPLP, while fHA 
exhibited the lowest amount of binding (Figure 4A). Comparison of the max. SS indicates that 
fcSAgAPLP:LAB binding was significantly greater than that of fcHAPLP, fcHALABL, and fcHA, 
while fcHAPLP binding was significantly greater than that of fcHALABL and fcHA (Figure 4B). 
Thus, multivalent PLP and LABL appear to have a cooperative effect on avidity. We previously 
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reported that SAgAPLP:LABL exhibited PLP-specific binding and BCR targeting, implying that 
PLP may enhance B cell avidity by providing specific affinity for the BCR. 44 Meanwhile, 
LABL, derived from LFA-1 and specific for ICAM-1, may enhance B cell avidity by promoting 
cell adhesion through the LFA-1/ICAM-1 interaction. 7, 11-13, 58-61  
Comparison of click-conjugated  versus hydrolyzable compound binding revealed that 
both fcSAgAPLP:LABL and fcHAPLP exhibited significantly enhanced binding compared to their 
hydrolyzable counterparts, fSAgAPLP:LABL and fHAPLP, respectively (Figure 4C). Differences in 
kinetics and max. SS binding between fcSAgAPLP:LABL, fSAgAPLP:LABL, and fHA illustrate how 
avidity is altered when multivalent peptide is conjugated to HA in a hydrolyzable versus non-
hydrolyzable manner (Figure 5AB). While both methods of multivalent modification resulted in 
significantly increased binding compared to the polymer alone, click-conjugated  
fcSAgAPLP:LABL exhibited significantly greater max. SS binding (p<0.001) than hydrolyzable 
SAgAPLP:LABL. Thus, multivalent co-presentation of PLP and LABL through non-hydrolyzable 
modification increased the avidity of the polymer array over hydrolyzable modification.  This 
result is supportive of literature stating that multivalent antigens exhibit superior binding avidity, 
higher ‘effective concentration’, and an enhanced ability to engage cell receptors compared to 
monovalent (or in this case, hydrolyzable) antigen. 27, 38, 39, 41, 62  
3.5 Calcium Flux Signaling Flow Cytometry Assay 
Flow cytometry calcium flux assays were used to compare the ability of SAgA and 
cSAgA molecules to modulate BCR-mediated signaling in Raji B cells. Signaling modulation 
was evaluated in Fluo-4 loaded Raji B cells prior to stimulation (Figure 5CD) and after 
stimulation (Figure 5EF) with crosslinking αIgM. The relative signal increase from resting 
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baseline (Figure 5D) or reduction from stimulated baseline (Figure 5F) was determined using 
mean Fluo-4 fluorescence values at steady state.  
We reported previously that SAgAPLP:LABL was capable of both inhibiting and reducing 
IgM-stimulated signaling. 44 Here, pre-treatment with SAgAPLP:LABL prior to addition of αIgM 
significantly inhibited IgM-stimulated calcium signaling compared to the vehicle (p<0.05) 
(Figure 5CD). However, pre-treatment with cSAgAPLP:LABL significantly inhibited IgM-
stimulated calcium signaling to a greater extent (p<0.01), largely preventing even the initial 
spike in calcium flux observed with SAgAPLP:LABL after αIgM addition. Similarly, addition of 
cSAgAPLP:LABL after αIgM stimulation caused a greater reduction in calcium signaling than 
SAgAPLP:LABL (p<0.01) (Figure 5EF). cSAgAPLP:LABL reduced signaling by ~60% while 
SAgAPLP:LABL reduced signaling by ~40% relative to the vehicle control. These results indicated 
that click-conjugated  cSAgAPLP:LABL is significantly more effective at dampening BCR-
mediated signaling – both through inhibition and reduction – compared to its hydrolyzable 
counterpart. 
Previously, we reported a significant reduction in signaling from addition of 
SAgAPLP:LABL, HAPLP, and HALABL, but negligible change in signaling from addition of vehicle 
(HBSS) or HA. 44 The click conjugates exhibited a similar trend: cSAgAPLP:LABL caused the 
greatest reduction in signaling while cHA caused the smallest reduction (p<0.05) (Figure 6A). 
However, while cSAgAPLP:LABL caused a greater reduction than hydrolyzable SAgAPLP:LABL, 
there was not a significant difference between cHAPLP vs. HAPLP and cHALABL vs. HALABL 
(Figure 6B). It is also interesting to note that cHA (HA-N3) caused a greater reduction than 
unmodified HA, which may be due to the presence of azide groups on the HA backbone leading 
to a greater degree of nonspecific binding. 
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3.6 Fluorescence Microscopy 
Fluorescence microscopy was performed with a microfluidics platform that enabled real 
time observation of binding and BCR clustering on the cell surface. Previously, we observed that 
fSAgAPLP:LABL binding induced mature receptor clustering in Raji B cells while the polymer 
alone did not, and concluded that LABL may contribute to the SAgAPLP:LABL molecule’s ability 
to cluster receptors. 44 Here, we observed receptor clustering following binding and also labeled 
IgM to monitor BCR organization on the cell surface. BCR clustering was observed in cells 
treated with fcHALABL (Figure 7C), fcHAPLP (Figure 7D), and fcSAgAPLP:LABL (Figure 7E) but 
not in those treated with unmodified fcHA polymer (Figure 7B). These trends echo our previous 
observations that multivalent polymer modified with PLP and LABL, but not unmodified HA, 
induced mature receptor clustering. BCR clustering in cells treated with fcSAgAPLP:LABL and 
fcHAPLP may be attributed in part to the antigen-specific binding affinity of PLP. BCR clustering 
in cells treated with fcHALABL may be promoted by the affinity of LABL for ICAM-1, since 
ICAM-1 clusters together with the BCR during signaling. 7, 11-13, 58-61 
These observations also corroborate the calcium flux results which show that cHAPLP, 
cHALABL, and in particular cSAgAPLP:LABL reduced BCR-mediated signaling to a greater extent 
than cHA. Combined with previous evidence supporting BCR as a target for SAgAPLP:LABL 
binding, 44 these results suggest that cSAgAPLP:LABL engagement and subsequent clustering of the 
BCR may dampen signaling. Our observations are consistent with reports that continuous BCR 
engagement and clustering are a mechanism for inducing B cell anergy that is accompanied by 
reduced calcium flux signaling. 34, 35 
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3.7 Clinical EAE Studies 
 Therapeutic efficacy of SAgAPLP:LABL and cSAgAPLP:LABL was evaluated in mice with 
EAE induced with PLP139-151 to model the relapsing-remitting form of MS. Disease symptoms 
emerged on day 10-12 with peak of disease occurring on day 13-15 before progressing to 
remission around day 20-25. Efficacy was measured by clinical score, weight change, and 
clinical score area under the curve (AUC) relative to the PBS control. AUC representation of 
clinical data has been reported as an informative secondary measure for overall extent of disease 
because it provides a cumulative measure not weighted by the scaling or time course of disease. 
63 Statistical differences were determined by comparing treated groups with the negative PBS 
control. 
 A three-day dosing schedule with a dose equivalent to 200 nmol PLP administered on 
days 4, 7, and 10 was found to be efficacious in previous SAgAPLP:LABL studies. 45-50 This dose 
and schedule was mirrored in a preliminary in vivo study with cSAgAPLP:LABL. It is important to 
note that shortly after the third administration on day 10, five out of six mice that received 
cSAgAPLP:LABL died from apparent anaphylaxis. Therefore, a combination of lower doses was 
investigated in a small-scale dosing study (Figure 8). To determine whether the total cumulative 
dose or the number of injections caused the negative response, a group was included with the 
same dose per injection (200 nmol PLP) but only administered on two days (days 4, 7). In 
another group, an equivalent cumulative dose was administered over three days (133 nmol PLP 
on days 4, 7, 10). A final group was included with a low dose of 50 nmol PLP, administered on 
all three days. All dosing groups significantly alleviated disease compared to the PBS control 
according to clinical disease score (Figure 8A) and clinical score AUC (Figure 8C). A 
cSAgAPLP:LABL dose of 50 nmol PLP caused a significant reduction in clinical score on the 
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greatest number of days (days 12-18) and exhibited the greatest reduction in clinical score AUC 
compared to PBS (p<0.001). Therefore, a cSAgAPLP:LABL dose of 50 nmol PLP was selected for 
studies going forward. 
 Next, in vivo efficacy of click-conjugated cSAgAPLP:LABL was compared to hydrolyzable 
SAgAPLP:LABL (Figure 9). At the original therapeutic dose equivalent to 200 nmol PLP, 
SAgAPLP:LABL significantly reduced clinical score on days 11-20 (Figure 9A) and significantly 
reduced total disease score AUC compared to PBS (p<0.0001) (Figure 9E). At only a quarter of 
the dose, cSAgAPLP:LABL (50 nmol PLP) significantly reduced total clinical score AUC to an 
equivalent extent as SAgAPLP:LABL at 200 nmol PLP (Figure 9E). Furthermore, cSAgAPLP:LABL 
(50 nmol PLP) significantly reduced clinical score on days 10-17 to a greater extent than 
SAgAPLP:LABL at the 200 nmol dose (Figure 9B). In contrast, the 50 nmol dose of SAgAPLP:LABL 
significantly reduced clinical score only on days 11 and 14 (Figure 9B), and reduced clinical 
score AUC to a significantly lesser extent (p<0.001) than cSAgAPLP:LABL (50 nmol PLP) (Figure 
9E). While SAgAPLP:LABL (200 nmol PLP) significantly alleviated weight loss on days 11-22 
(Figure 9C), cSAgAPLP:LABL (50 nmol PLP) significantly alleviated weight loss over a larger 
portion of the study, on days 11-25 (Figure 9D). In contrast, SAgAPLP:LABL (50 nmol PLP) did 
not alleviate weight loss on any day of the study (Figure 9D). 
cSAgAPLP:LABL achieved equivalent in vivo efficacy as SAgAPLP:LABL at one quarter of the 
antigen dose. Thus, compared to hydrolyzable multivalent modification, non-hydrolyzable click 
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4. Conclusions 
Here we present the development of click-conjugated  multivalent soluble antigen arrays 
and their evaluation in vitro and in vivo as therapeutic agents in a murine model of MS. 
Hydrolyzable SAgAPLP:LABL, which we have studied extensively, 44-50 employs a degradable 
linker to co-deliver antigen (PLP) and cell adhesion inhibitor (LABL) peptides, and has been 
shown to significantly suppress EAE. cSAgAPLP:LABL is a modified version of the SAgAPLP:LABL 
molecule with multiple PLP and LABL peptides conjugated to HA using non-hydrolyzable 
linker chemistry (Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC)). Building upon 
previous work, these studies sought to establish therapeutic efficacy of cSAgAPLP:LABL in vivo 
while identifying a potential therapeutic mechanism by evaluating binding avidity and signaling 
modulation in vitro. Click-conjugated  cSAgAPLP:LABL exhibited greatly enhanced binding in B 
cells compared to hydrolyzable SAgAPLP:LABL, indicating that non-hydrolyzable multivalent 
ligand increases the avidity of the molecule. Furthermore, cSAgAPLP:LABL exhibited greater 
capacity for reducing and inhibiting BCR-mediated signaling as compared to SAgAPLP:LABL. 
Imaging revealed that cSAgAPLP:LABL binding caused BCR clustering, another marker indicative 
of BCR engagement and signaling modulation. Lastly, cSAgAPLP:LABL exhibited enhanced in 
vivo efficacy against EAE, achieving equivalent efficacy as SAgAPLP:LABL at one quarter of the 
dose. Taken together, these results indicate that non-hydrolyzable conjugation increases the 
avidity of cSAgAPLP:LABL, and this enhanced binding drives in vivo efficacy through modulated 
BCR-mediated signaling.  
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Table 1. Peptide molar conjugation of hydrolyzable and click conjugates was determined by 
reverse-phase HPLC. Results are an average of triplicate injections from a single batch 
preparation. In the molecule schematics, dotted lines represent hydrolyzable oxime linker 
chemistry while solid lines represent non-hydrolyzable ‘click’ linker chemistry. 
Sample Approx. MW (kDa)a 




PLP:HA LABL:HA PLP LABL 
HAPLP 
      
30.4  9 0 21 0 
HALABL 
      
26.0  0 10 0 24 
SAgAPLP:LABL 
      
46.3 10 13 24 31 
cHAPLP 
      
41.2 10 0 24 0 
cHALABL 
      
37.2 0 12 0 28 
cSAgAPLP:LABL 
      
52.1 11 9 26 21 
a Calculated from RP-HPLC data. MW, molecular weight. 
b HA, hyaluronic acid; PLP, proteolipid protein peptide; LABL, inhibitor peptide derived from 
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Scheme 2: Synthesis of cSAgA multivalent arrays. 
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Figure 2: Representative HPLC chromatograms used to quantify the number of conjugated 
peptides as a function of reaction temperature.  Chromatographic conditions – column: Waters 
XBridge C4, 300 Å, 3.5 µm, 4.6x150 mm; Mobile Phase A: 0.05% TFA in H2O; Mobile Phase 
B: 0.05% TFA in MeCN; 5-60% B gradient elution over 14 min; Detection: UV at 214 nm. 
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Figure 3: Qualitative confirmation of conjugation by 13C DEPT-135 NMR spectroscopy, where 
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Figure 4. Binding of fcHA, fcHALABL, fcHAPLP, and fcSAgAPLP:LABL with Raji B cells 
determined by flow cytometry: (A) Binding kinetics showing association through steady state. 
(B) Relative binding at maximum steady state (max. SS). (C) Comparison of max. SS binding 
with hydrolyzable versus click-conjugated arrays. Statistical significance determined by 
ANOVA followed by Tukey’s (B) or Sidak’s (C) post hoc test with p<0.05 and n=3 (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001). Robust curve fitting in (A) was performed using 
sigmoidal nonlinear regression.  
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Figure 5. Comparing SAgAPLP:LABL and cSAgAPLP:LABL binding and IgM-stimulated (BCR-
mediated) calcium flux signaling in Raji B cells through flow cytometry assays: (A) Binding 
kinetics and (B) maximum steady state (max. SS) binding with fSAgAPLP:LABL, fcSAgAPLP:LABL, 
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and fcHA. (C) Calcium flux inhibition: Fluo-4 loaded cells were first pretreated with vehicle 
(HBSS), SAgAPLP:LABL, or cSAgAPLP:LABL, then stimulated with anti-IgM (αIgM, black arrow) to 
evaluate signaling inhibition. (D) Relative IgM signaling stimulation following pretreatment; 
baseline-adjusted values determined from mean steady state values. (E) Calcium flux reduction: 
Fluo-4 loaded cells were first stimulated with αIgM at ~30 s (black arrow), then treated with 
vehicle (HBSS), SAgAPLP:LABL, or cSAgAPLP:LABL after ~60 s (black arrow) to evaluate signaling 
reduction. (F) Percent reduction from IgM-stimulated baseline following sample addition, 
determined from mean steady state values. Statistical significance was determined by ANOVA 
followed by Tukey’s post hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). Calcium flux kinetics in (C) and (D) show median Fluo-4 fluorescence values. 
Robust curve fitting in (A) was performed using sigmoidal nonlinear regression. Calcium flux 
data was pooled from three independent experiments. 
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Figure 6. Reduction in IgM-stimulated (BCR-mediated) calcium flux signaling in Fluo-4 loaded 
Raji B cells determined by flow cytometry: (A) Percent reduction from αIgM-stimulated baseline 
following addition of cHA, cHALABL, cHAPLP, or cSAgAPLP:LABL, determined from mean steady 
state values. (B) Comparison of reduction in αIgM-stimulated signaling from hydrolyzable 
versus click-conjugated arrays. Data was pooled from three independent experiments. Statistical 
significance was determined by ANOVA followed by Tukey’s post hoc test (A) or unpaired t-
test (B) with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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Figure 7. Fluorescence microscopy showing binding and BCR clustering in Raji B cells 
following perfusion of (A) vehicle, (B) fcHA, (C) fcHALABL, (D) fcHAPLP, and (E) 
fcSAgAPLP:LABL. Cell nuclei were stained with Hoechst (violet – Panel 1) and surface IgM was 
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stained with AlexaFluor 647-conjugated αIgM (blue – Panel 3). Penn Green-labeled polymer 
arrays are shown binding to the cell surface (green – Panel 2). In contrast to the diffuse IgM 
fluorescence in (A), highly localized punctate IgM fluorescence in (C), (D), and (E) indicates 
BCR clustering in cells treated with fcHALABL, fcHAPLP, and fcSAgAPLP:LABL. Captured using the 
M04S plate and CellASIC Onyx Microfluidics platform on an Olympus IX81 inverted 
Epifluorescence microscope. Magnification: 60X air. Scale bar equals 10 µm. 
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Figure 8. Clinical EAE dosing study with cSAgAPLP:LABL: cSAgAPLP:LABL was administered on 
days 4 and 7 at a dose equivalent to 200 nmol PLP and on days 4, 7, and 10 at a dose equivalent 
to 50 or 133 nmol PLP. Therapeutic efficacy evaluated by comparing (A) clinical disease score, 
(B) percent weight change, and (C) clinical score area under the curve (AUC). Statistical 
significance (compared to the negative PBS control) was determined by ANOVA followed by 
Tukey’s post hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, #/***p<0.001, 
##/****p<0.0001). 
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Figure 9. Comparing SAgAPLP:LABL and cSAgAPLP:LABL therapeutic efficacy in EAE: (A) 
SAgAPLP:LABL (200 nmol PLP dose) clinical scores (n=6), (B) cSAgAPLP:LABL versus 
SAgAPLP:LABL (50 nmol PLP dose) clinical scores (n=5), (C) SAgAPLP:LABL (200 nmol PLP dose) 
weight change, (D) cSAgAPLP:LABL versus SAgAPLP:LABL (50 nmol PLP dose) weight change, and 
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(E) clinical score area under the curve (AUC) relative to PBS. Statistical significance was 
determined by ANOVA followed by Dunnet’s (A-D) or Tukey’s (E) post hoc test with p<0.05 
(*p<0.05, **p<0.01, #/***p<0.001, ##/****p<0.0001).  
	  




Supplemental Figure 1. Raji B cell calcium binding gating scheme: A) Identify single cells and 
gate out doublets; B) Identify live cells and gate out dead cells and debris; C) Plot FITC vs. time 
and identify steady state region (shown as gate B). 
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Chapter V: Conclusions and Future Work 
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1. Conclusions 
Multivalent soluble antigen arrays have emerged as a promising option for antigen-
specific immunotherapy (ASIT) with potential to modulate the immune response to specific, 
disease-causing autoantigens. Creation of antigen-specific tolerogenic therapies in humans would 
be groundbreaking, reducing or eliminating the risk of global immunosuppression in the 
treatment of autoimmune disease. As reviewed in Chapter 1, multivalent antigen presentation has 
long been utilized in vaccine design to elicit an antigen-specific immunogenic response, but has 
since evolved for applications where immune tolerance is desired, such as reversing 
autoimmunity. Nanomaterials can be engineered to have specific physicochemical properties 
(i.e., size, charge, and shape) to influence biodistribution and immune response, while 
multivalent ligand display (i.e., number, density, ratio, and incorporation of secondary inhibitory 
signals) can be tailored to direct the cellular response towards tolerance versus immunogenicity.  
Multivalent soluble antigen arrays (SAgAPLP:LABL) were designed using this rationale, 
consisting of a flexible hyaluronic acid (HA) linear polymer backbone co-grafted with multiple 
copies of autoantigen peptide (PLP) and cell adhesion inhibitor peptide (LABL), to induce 
tolerance to a specific multiple sclerosis autoantigen. Previous studies showed that SAgAPLP:LABL 
significantly alleviated disease in EAE, a murine model of MS. 1-3 Our original hypothesis was 
that the two signals, PLP and LABL, enabled SAgAPLP:LABL to target antigen presenting cells 
(APCs) and interrupt signaling during the immunological synapse, which requires both a primary 
antigenic signal and secondary costimulatory signal to activate T cells against autoantigen. 
Chapters 2, 3, and 4 sought to evaluate this hypothesis and elucidate therapeutic cellular 
mechanisms while identifying molecular properties that contribute to therapeutic efficacy against 
EAE.  
	  
	   172	  
In Chapter 2, we explored the role of two-signal co-delivery in determining SAgAPLP:LABL 
therapeutic potential by evaluating EAE clinical results, in silico molecular dynamics 
simulations, and nanomaterial properties for various covalent and physical combinations of HA, 
PLP, and LABL. Only SAgAPLP:LABL and a mixture of HAPLP+HALABL were therapeutic against 
EAE, while a mixture of the components (HA+ PLP+LABL), HA alone, HA grafted with PLP 
only (HAPLP), and HA grafted with LABL only (HALABL) were not, indicating that co-
presentation of both signals on HA was necessary for therapeutic efficacy. Molecular dynamics 
simulations revealed that stable intermolecular interactions and chain entanglement between 
HAPLP and HALABL in the homopolymer mixture likely facilitated co-transport of the two signals. 
The results suggested that co-delivery of both primary autoantigen and secondary inhibitory 
signal in the same spatial and temporal context was necessary for therapeutic efficacy, and that 
SAgAPLP:LABL provided an effective platform for two-signal co-delivery. 
In Chapter 3, we investigated the SAgAPLP:LABL cellular mechanism in a model B cell 
system by evaluating binding, specificity, and signaling modulation in vitro. These studies were 
based on the hypothesis that SAgAPLP:LABL targets B cells (as APCs) and inhibits antigen-specific 
signaling to mediate the autoimmune response. Indeed, SAgAPLP:LABL exhibited enhanced B cell 
binding compared to HA, HAPLP, and HALABL. Specific binding was driven by the PLP peptide 
and it was determined through IgM blocking studies that BCR was a target of SAgAPLP:LABL 
binding, supporting our hypothesis that SAgAPLP:LABL targets B cells in an antigen-specific 
manner. SAgAPLP:LABL induced mature receptor clustering to a greater extent than HA, HAPLP, or 
HALABL, which correlated with greater reduction in BCR-mediated calcium signaling. Taken 
together, these results indicated that mechanisms of enhanced antigen-specific binding, mature 
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receptor clustering, and dampened BCR-mediated signaling in B cells may contribute to 
SAgAPLP:LABL therapeutic efficacy.  
In Chapter 4, we developed new click-conjugated multivalent soluble antigen arrays and 
evaluated them in vitro and in vivo as therapeutic agents in EAE. Hydrolyzable SAgAPLP:LABL, 
studied up to this point, employed a degradable linker to codeliver antigen (PLP) and cell 
adhesion inhibitor (LABL) peptides. This approach was consistent with our earlier two-signal 
hypothesis of SAgA molecules, which would necessitate antigen uptake, processing, and 
presentation. Conversely, ‘click SAgAPLP:LABL’, or cSAgAPLP:LABL, is a modified version of the 
SAgAPLP:LABL molecule with multiple PLP and LABL peptides conjugated to HA using non-
hydrolyzable linker chemistry (Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC)). 
Building upon work from Chapter 3, these studies sought to establish therapeutic efficacy of 
cSAgAPLP:LABL in vivo while identifying a potential therapeutic mechanism by evaluating binding 
avidity and signaling modulation in vitro. Click-conjugated cSAgAPLP:LABL exhibited greatly 
enhanced binding in B cells compared to hydrolyzable SAgAPLP:LABL, indicating that non-
hydrolyzable multivalent ligand increased the avidity of the molecule. Furthermore, 
cSAgAPLP:LABL exhibited greater capacity for reducing and inhibiting BCR-mediated signaling as 
compared to SAgAPLP:LABL. Imaging revealed that cSAgAPLP:LABL binding caused BCR 
clustering, another marker indicative of BCR engagement and signaling modulation. Lastly, 
cSAgAPLP:LABL exhibited significantly enhanced in vivo efficacy against EAE, achieving 
equivalent efficacy as SAgAPLP:LABL at only a quarter of the dose. Taken together, these results 
indicated that non-hydrolyzable conjugation increased the avidity of cSAgAPLP:LABL and that 
enhanced binding drives in vivo efficacy through modulated BCR-mediated signaling.  
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To conclude, this dissertation covered the development of multivalent soluble antigen 
arrays as a promising option for ASIT while elucidating molecular and cellular mechanisms that 
contribute to therapeutic efficacy against EAE. The molecular properties of (1) multivalent 
presentation of antigen, (2) co-presentation of autoantigen and adhesion inhibitor, and (3) non-
hydrolyzable conjugation were combined in cSAgAPLP:LABL to achieve significant therapeutic 
efficacy in EAE. Results from Chapters 3 and 4 disputed our early two-signal hypothesis that 
SAgAs target the immunological synapse, and instead pointed to a mechanism in which SAgAs 
target BCR signaling while remaining on the cell surface. These results indicated that efficacy 
was driven by enhanced, antigen-specific binding with B cells and subsequent dampening of 
BCR-mediated signaling. Enhanced binding avidity may be attributed to combined affinities of 
both PLP-driven specific binding and LABL-promoted adhesion. Antigen-specific targeting of 
the BCR was supported by binding and imaging studies that showed BCR binding and 
clustering, and by calcium flux studies that showed modulation of BCR-mediated signaling. 
These observations are consistent with B cell anergy, a state of antigen unresponsiveness that is 
induced through continuous BCR binding, occupation, and clustering in the absence of 
secondary costimulatory signal and marked by reduced calcium flux signaling. 4-7 Thus, our 
conclusions point to B cell anergy as the cSAgAPLP:LABL therapeutic mechanism and present a 
promising strategy for inducing antigen-specific tolerance in autoimmunity. 
 
2. Future Work 
Thus far, we have drilled into the cSAgAPLP:LABL cellular mechanism in the context of an 
immortalized B cell line and our results have pointed to the induction of B cell anergy. However, 
the cellular mechanism should be evaluated in a disease-specific primary cell system to fully 
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understand how SAgAs are interacting in an antigen-educated mixed cell population. Ongoing 
work in our laboratory has been seeking to determine whether multivalent soluble antigen arrays 
target B cells in an EAE mouse splenocyte mixed immune cell population and whether this 
results in an anergic phenotype. 
cSAgA binding and targeting was evaluated ex vivo in mixed splenocytes isolated from 
healthy and EAE mice using flow cytometry binding assays developed in Chapter 3. Splenocytes 
were antibody-labeled for B cells (CD19+), T cells (CD3+), and dendritic cells (CD11c+). 
Binding trends again reflected those observed in Chapters 3 and 4, where fcSAgAPLP:LABL 
exhibited the highest amount of binding followed by fcHAPLP (Figure 1). fcSAgAPLP:LABL 
preferentially targeted B cells, in particular a subclass of B cells called autoimmune-associated B 
cells (ABCs) (CD19+CD11c+) that are potent antigen presenting cells found in the spleen during 
autoimmune disease (Figure 1B, Figure 2). 8-10 Furthermore, binding was significantly higher in 
EAE B cells than healthy B cells, indicating disease-specific targeting, which was not the case in 
T cells (Figure 3). These results support our hypothesis that soluble antigen arrays target B cells 
and APCs over other cell types, and do so in a disease-specific manner.  
In addition to reduced calcium flux signaling, another result of B cell anergy is down-
regulation of costimulatory markers such as CD80 and CD86. 4-7 Costimulatory signal 
presentation by APCs is essential for autoreactive T cell activation; reception of a primary 
antigenic signal in the absence of a secondary costimulatory signal leads to T cell anergy. 11-14 
Induction of B cell anergy can therefore have a two-fold therapeutic effect by inducing (1) an 
effector B cell population that is not responsive to autoantigen and (2) B cells with reduced APC 
capacity.  
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Thus, we investigated CD80/CD86 expression in splenocytes under two conditions: (1) 
harvested from EAE mice at peak of disease and treated in vitro during simultaneous PLP 
challenge to evaluate the effect on costimulatory signaling, and (2) harvested from mice treated 
in vivo and re-challenged with PLP ex vivo to evaluate lasting tolerance. First, in vitro treatment 
with cSAgAPLP:LABL, cHAPLP, and cHAPLP+cHALABL caused significant down-regulation of 
CD86 in EAE splenocytes harvested from mice at peak of disease, causing B cells and 
autoimmune-associated B cells (ABCs) to signal more like healthy cells rather than activated 
APCs (Figure 4BC). Furthermore, in vivo treatment with cSAgAPLP:LABL, cHAPLP, and 
cHAPLP+cHALABL significantly alleviated disease in EAE (Figure 4A). Upon ex vivo rechallenge 
with PLP, B cells and ABCs from these mice did not respond with a significant increase in 
CD80/CD86 expression like the PBS control, again behaving more like healthy cells (Figure 
4DE). Combined, these results indicate that treatment with cSAgAPLP:LABL, cHAPLP, and 
cHAPLP+cHALABL induced PLP-specific anergy in B cells, resulting in reduced APC capacity and 
lasting tolerance to autoantigen. 
 These exciting preliminary results have encouraged us to continue exploring cSAgA as a 
therapeutic platform, B cells as a therapeutic target, and induction of B cell anergy as a 
therapeutic cellular mechanism. In particular, autoimmune-associated B cells have emerged as a 
therapeutic target of interest; specific targeting and effects on this population should be 
investigated in future work. Additional studies should be performed to validate B cell anergy as 
the cellular mechanism in EAE splenocytes. Calcium flux signaling assays will be performed in 
antibody-labeled splenocytes to determine whether BCR-mediated signaling is reduced in 
primary B cells, as in Raji B cells. Reduction of BCR-mediated signaling in EAE B cells (while 
unchanged in healthy B cells) would indicate that cSAgAPLP:LABL is acting in an antigen-specific 
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manner. Another result of B cell anergy is apoptosis and reduced B cell lifespan. 4-6, 12 Thus, 
induction of anergy may be explored by evaluating apoptosis and cell death through flow 
cytometry assays (i.e., using Annexin-V/PI staining) in antibody-labeled splenocytes. Again, 
increased apoptosis in EAE B cells over healthy B cells would suggest an antigen-specific 
mechanism.  
Downstream T cell response should be investigated to reveal whether T cell activation is 
in fact inhibited as a result of the observed B cell anergic behavior. IL-2, TNF-α, and IFN-γ are 
key cytokines associated with an inflammatory T cell response, while IL-10 is associated with 
anergy and a regulatory lymphocyte response. These cytokines will be measured in EAE 
splenocytes following in vivo treatment and in vitro PLP rechallenge using enzyme-linked 
immunosorbent analysis (ELISA) to identify a reduction in T cell activation and shift towards a 
regulatory response. T cell activation, which triggers T cell clonal expansion, may also be 
evaluated using a carboxyfluorescein succinimidyl ester (CFSE) flow cytometry assay to 
measure T cell proliferation in EAE splenocytes following in vitro treatment with 
cSAgAPLP:LABL. 
Our in vivo results point to another avenue to explore. cHAPLP (with a conjugation of ~15 
PLP per backbone) exhibited significant therapeutic efficacy in vivo, to a similar extent as 
cSAgAPLP:LABL (with a conjugation of ~10 PLP and ~10 LABL per backbone) (Figure 4A). 
cHAPLP in vivo efficacy was matched by significant reduction in CD80/CD86 expression in EAE 
splenocytes (Figure 4B-E). These results suggests that non-hydrolyzable conjugation of antigen 
at a slightly higher valency may enhance avidity to a similar extent as two signals in 
cSAgAPLP:LABL. It will be interesting in future studies to investigate varying antigen valency in 
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cHAPLP and the effect on B cell binding, BCR-mediated signaling, and therapeutic efficacy in 
vivo.  
Finally, multivalent soluble antigen arrays provide a versatile and translatable platform 
with tremendous potential for application to other autoimmune diseases. This is particularly the 
case now that we have identified cornerstone therapeutic molecular properties and a probable 
therapeutic cellular mechanism. Additionally, the versatility of the click conjugation reaction in 
the new cSAgA platform enables improved control over valency and ligand selection. cSAgA 
can be applied to other autoimmune diseases that are propagated by a B cell response by 
changing the autoantigen to one that is disease-specific. For example, cSAgA can be applied to 
type 1 diabetes by conjugating hormonally inactive insulin to the HA backbone in various 
contexts. Ongoing work in this area will continue to strengthen our understanding of antigen-
specific multivalent immunotherapies and refine the design criteria needed to develop better 
ASIT to treat autoimmune disease.  
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Figure 1. Maximum steady state (max. SS) binding in antibody-labeled splenocytes isolated 
from EAE and healthy mice determined by flow cytometry, comparing binding of fluorescently-
labeled click conjugates with (A) CD19+ B cells and (B) CD19+CD11c+ autoimmune-associated 
B cells (ABCs). Splenocytes were isolated from mice at peak of disease and cultured for 72 hr 
prior to the experiment. Statistical significance (between fcHA, fcHALABL, fcHAPLP, and 
fcSAgAPLP:LABL) was determined by ANOVA followed by Tukey’s post hoc test with p<0.05 and 
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Figure 2. Fluorescence microscopy showing binding of Penn Green-labeled fcSAgAPLP:LABL 
(Panel 3) with CD19+CD11c+ autoimmune-associated B cells (ABCs) isolated from the spleen of 
an EAE mouse. Splenocytes were antibody-labeled with Pacific Blue-conjugated CD11c (Panel 
1) and AlexaFluor 647-conjugated CD19 (Panel 2) to identify ABCs. Captured using the M04S 
plate and CellASIC Onyx Microfluidics platform on an Olympus IX81 inverted Epifluorescence 
microscope. Magnification: 60X air.  
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Figure 3. Maximum steady state (max. SS) binding in antibody-labeled splenocytes isolated 
from EAE and healthy mice determined by flow cytometry, comparing binding of fluorescently-
labeled click conjugates with (A) CD19+ B cells and (B) CD3+ T cells. Splenocytes were isolated 
from mice at peak of disease and cultured for 72 hr prior to the experiment. Statistical 
significance (between healthy and EAE) was determined by ANOVA followed by Tukey’s post 
hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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Figure 4. Costimulatory marker expression was evaluated in antibody-labeled EAE splenocytes 
following in vitro or in vivo treatment with click conjugates. (A) EAE clinical disease score area 
under the curve (AUC) indicated significant therapeutic efficacy from in vivo treatment with 
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cHAPLP, cSAgAPLP:LABL, and cHAPLP+cHALABL (50 nmol PLP dose). (B/C) Splenocytes isolated 
from EAE mice at peak of disease were treated with the groups from (A) for 72 hr in vitro in the 
presence or absence of PLP. CD86 expression (anti-CD86 mean fluorescence intensity, MFI) 
was evaluated by flow cytometry in (B) CD19+ B cells and (C) CD19+CD11c+B220+ 
autoimmune-associated B cells (ABCs) to evaluate APC costimulatory signaling. (D/E) 
Splenocytes isolated from mice on day 25 following in vivo treatment in (A) were rechallenged 
with/without PLP for 72 hr. CD86 expression was evaluated by flow cytometry in (B) CD19+ B 
cells and (C) CD19+CD11c+B220+ ABCs to evaluate lasting tolerance to autoantigen. Statistical 
significance (compared to the negative PBS control) was determined by ANOVA followed by 
Tukey’s post hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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